Introduction {#s1}
============

Serotonin or 5-hydroxytryptamine (5-HT) is a chemical messenger which acts on cells throughout the human body, beginning in early development and throughout adulthood ([@bib6]). 5-HT acts as both a neurotransmitter and a hormone that regulates blood vessel constriction and intestinal motility ([@bib6]). In the central nervous system, 5-HT is released from presynaptic neurons where it diffuses across the synaptic space and binds to 5-HT receptors, promoting downstream signaling and activating postsynaptic neurons ([@bib20]; [@bib28]). Thus, 5-HT is a master regulator of circuits, physiology and behavioral functions including the sleep/wake cycle, sexual interest, locomotion, thermoregulation, hunger, mood, and pain ([@bib6]). 5-HT is cleared from synapses and taken into presynaptic neurons by the serotonin transporter (SERT), thus terminating serotonergic signaling ([@bib20]; [@bib28]; [@bib43]). SERT resides in the plasma membrane of neurons and belongs to a family of neurotransmitter sodium symporters (NSSs) which also includes the dopamine (DAT) and norepinephrine transporters (NET) ([@bib20]; [@bib28]; [@bib43]). NSSs are twelve transmembrane spanning secondary active transporters which utilize sodium and chloride gradients to energize the transport of neurotransmitter across the membrane ([@bib43]; [@bib32]; [@bib51]; [Figure 1a](#fig1){ref-type="fig"}).

![Topology of SERT.\
(**a**) The substrate is bound at the central site (sand, triangle), near two sodium ions (purple, spheres +) and a chloride ion (green, sphere -). The light orange and light blue triangles depict pseudo two-fold symmetric helical repeats comprised of TM1-5 and 6--10, respectively. The disulfide bond (purple line) and *N*-linked glycosylation (red 'Y' shapes) in extracellular loop 2, along with sites of thermostable mutations (Tyr110Ala, TM1a; Ile291Ala, TM5; Thr439Ser, TM8) are also shown (cyan-filled circles). Structural elements involved in binding allosteric ligands are depicted as black-filled circles. Epitopes for the 8B6 and 15B8 Fab binding sites are in squiggly dark-blue and orange lines, respectively. (**b**) Schematic of the ABC pose of paroxetine bound to the central binding site, derived from the previously determined x-ray structures ([@bib16]; [@bib13]). The transmembrane helices are shown with circles and mutated residues in subsite B are in sticks. c, The ACB pose of paroxetine bound to the central binding site of SERT predicted by molecular dynamics simulations and mutagenesis ([@bib1]; [@bib45]).](elife-56427-fig1){#fig1}

The function of NSSs is modulated by a spectrum of small-molecule drugs, thus in turn controlling the availability of neurotransmitter at synapses. Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs which inhibit SERT and are used to treat major depression and anxiety disorders ([@bib12]). Using x-ray crystallography and cryo-EM, we have determined structures of thermostabilized variants of human SERT complexed with SSRIs, which together explain many of the common features and differences associated with SERT-SSRI interactions ([@bib16]; [@bib13]). SSRIs are competitive inhibitors that bind with high-affinity and specificity to a central substrate-binding site in SERT, preventing 5-HT binding and arresting SERT in an outward-open conformation ([@bib20]; [@bib28]; [@bib13]).

The central site in NSSs is composed of three subsites: A, B, and C ([@bib47]; [Figure 1b](#fig1){ref-type="fig"}). In all NSS-ligand structures, the amine group of ligands resides in subsite A and interacts with a conserved Asp residue (Asp98 in SERT). The heterocyclic electronegative group of the ligand is positioned in subsite B ([@bib32]). For example, the alkoxyphenoxy groups of reboxetine and nisoxetine ([@bib35]) in *Drosophila* DAT (dDAT) structures, the halophenyl groups of cocaine analogs in dDAT and *S*-citalopram in SERT, and the catechol derivatives in DCP-dDAT and sertraline-SERT all occupy subsite B ([@bib16]; [@bib13]; [@bib48]). In addition to the central binding site, the activity of SERT and NSSs can also be modulated by small-molecules which bind to an allosteric site located in an extracellular vestibule, typically resulting in non-competitive inhibition of transport ([@bib13]; [@bib54]; [@bib50]; [@bib37]).

Paroxetine is an SSRI which exhibits the highest known binding affinity for the central site of SERT (70.2 ± 0.6 pM) compared to any other currently prescribed antidepressants ([@bib17]). Despite its high affinity, paroxetine is frequently associated with serious side effects including infertility, birth defects, cognitive impairment, sexual dysfunction, weight gain, suicidality, and cardiovascular issues ([@bib33]). As a result, the mechanism of paroxetine binding to SERT has been studied extensively in order to design drugs with higher-specificity and less adverse side-effects. Despite these efforts, however, the binding pose of paroxetine remains a subject of debate ([@bib16]; [@bib13]; [@bib1]; [@bib18]; [@bib45]).

Paroxetine is composed of a secondary amine which resides in a piperidine ring, which in turn is connected to benzodioxol and fluorophenyl groups ([Figure 1b](#fig1){ref-type="fig"}). X-ray structures of the SERT-paroxetine complex revealed that the piperidine ring binds to subsite A while the benzodioxol and fluorophenyl groups occupy subsite B and C in the central site, respectively ([@bib16]; [@bib13]) (ABC pose, [Figure 1b](#fig1){ref-type="fig"}). However, recent mutagenesis, molecular dynamics, and binding studies with paroxetine analogues suggest that paroxetine might either occupy ABC pose as observed in the crystal structure, or an ACB pose where the benzodioxol and fluorophenyl groups occupy subsite C and B of the central site respectively ([@bib1]; [@bib45]; [Figure 1c](#fig1){ref-type="fig"}). Paroxetine is also thought to interact with the allosteric site of SERT, albeit with low-affinity ([@bib37]). We have, however, been unable to visualize paroxetine binding at the allosteric site using structural methods. Our x-ray maps, by contrast, resolve a density feature at the allosteric site which instead resembles a molecule of detergent ([@bib13]).

To resolve the ambiguity of paroxetine binding poses at the central binding site, we turned to paroxetine derivatives whereby the 4-fluoro group is substituted with either a bromine or an iodine group. Using transport and binding assays, anomalous x-ray diffraction, and cryo-EM, we have examined the binding poses of these paroxetine analogs and their interactions at the central site. Our studies provide key insights into the recognition of high-affinity inhibitors by SERT and the rational design of new small-molecule therapeutics.

Results {#s2}
=======

To provide a robust molecular basis for the interaction of paroxetine (**1**) with SERT, we devised synthetic routes for two derivatives of paroxetine where the 4-fluoro moiety is substituted with either bromo (Br-paroxetine, 2) or iodo (I-paroxetine, 3) groups ([Figure 2a,b](#fig2){ref-type="fig"}). We envisaged the use of a C--H functionalization strategy to access enantiopure hydroxymethyl intermediates **I**, from readily available *N*-Boc (*R*)-nipecotic acid 4 ([Figure 2b](#fig2){ref-type="fig"}, Appendix 1). Transition metal-catalyzed C--H functionalization can promote the reaction of unactivated C(sp^3^)--H bonds with the aid of a directing group ([@bib23]; [@bib40]; [@bib5]; [@bib34]; [@bib30]; [@bib9]). Here, C--H functionalization enabled installation of the appropriate aryl group on the pre-existing piperidine ring ([@bib4]), providing an attractive and short route to vary this functionality with inherent control of enantiomeric excess. In contrast, common methods for (--)-paroxetine synthesis can require the aromatic substituent to be introduced before stereoselective steps or ring construction, reducing flexibility of the process ([@bib45]; [@bib25]; [@bib24]; [@bib7]; [@bib27]; [@bib49]; [@bib29]; [@bib3]). Nevertheless, during the preparation of this work, the synthesis of Br-paroxetine was reported using an asymmetric conjugate addition and its binding to SERT has been extensively studied ([@bib45]; [@bib7]).

![Synthesis of paroxetine analogues.\
(**a**) Structures of (--)-paroxetine (1) and the targeted Br- (2) and I-analogues (3). (**b**) Retrosynthetic analysis of Br- and I-(--)-paroxetine. (**c**) Synthesis of Br- and I-(--)-paroxetine 2 and 3. Q = 8 quinolinyl-. Reaction conditions: *i*) X = Br: (--)−5 (4.0 mmol), 4-bromo iodobenzene (three equiv), Pd(OAc)~2~ (5 mol %), K~2~CO~3~ (one equiv), PivOH (one equiv), Ph-CF~3~ (2 mL, 2 M), 110°C, 18 hr; *ii*) X = I: (--)−5 (4.0 mmol), 1,4-diiodobenzene (four equiv), Pd(OAc)~2~ (5 mol %), K~2~CO~3~ (one equiv), PivOH (one equiv), Ph-CF~3~ (2 mL, 2 M), 110°C, 18 hr; *iii*) DBU (three equiv), toluene (1 M), 110°C, 24 hr; *iv*) Boc~2~O (four equiv), DMAP (20 mol %), CH~3~CN (0.5 M), 35°C, 22 hr; *v*) LiAlH~4~ (two equiv), THF, 20°C, 0.5 hr; *vi*) MsCl (1.3 equiv), Et~3~N (1.4 equiv), CH~2~Cl~2~, 0 to 25°C, 2 hr; *vii*) X = Br: sesamol (1.6 equiv), NaH (1.7 equiv), THF, 0°C to 70°C, 18 hr; *viii*) X = I: sesamol (2.0 equiv), NaH (2.2 equiv), DMF, 0°C to 90°C, 20 hr; *ix*) 4 N HCl in dioxane (10 equiv), 0°C to 25°C, 18 hr.](elife-56427-fig2){#fig2}

Our synthesis commenced with the C--H arylation of piperidine (--)−5 bearing Daugulis' aminoquinoline amide directing group ([@bib52]) at C(3). Adapting our reported method ([@bib4]), Pd-catalyzed C--H functionalization was achieved in moderate yields using 4-bromoiodobenzene or 1,4-diiodobenzene in excess to prevent bis-functionalization, with palladium acetate, K~2~CO~3~ and pivalic acid ([Figure 2c](#fig2){ref-type="fig"}). The *cis-*arylated derivatives (+)−6a and (+)−6b were obtained with \> 98% *ee* and complete C(4) selectivity. Minor enantiopure *trans*-functionalized products, formed via a *trans*-palladacycle ([@bib4]), were also isolated (Appendix 1). Subsequent treatment with 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) gave complete C(3)-epimerization affording (+)−7a and (+)−7b with the desired *trans-*stereochemistry in 94% and 91% yields. The aminoquinoline group was removed through telescoped amide activation and reduction with LiAlH~4~ at 20°C to give enantiopure hydroxymethyl intermediates (--)−8a and (--)−8b in 77% and 75% yield. Mesylation and nucleophilic substitution with sesamol formed ether derivatives (--)−9a and (--)−9b, which were deprotected to give Br- and I-paroxetine 2 and 3. An overall yield of 12% over 8 steps from commercial material was obtained in both cases. At each stage, the identity of the products and purity was established by acquiring ^1^H and ^13^C nuclear magnetic resonance spectra, IR spectra, and by high-resolution mass spectrometry [Supplementary files 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}. Enantiopurity was assessed by high-performance liquid chromatography (HPLC) with reference to racemic or scalemic samples ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

We also employed several SERT variants and the 8B6 Fab in the biochemical and structural studies described here. The wild-type SERT construct used in transport experiments contains the full-length SERT sequence fused to a C-terminal GFP tag ([Table 1](#table1){ref-type="table"}). The ts2-active variant contains two thermostabilizing mutations (Ile291Ala, Thr439Ser) which allows for purification of the apo transporter for binding studies and has kinetics of 5-HT transport (K~m~: 4.5 ± 0.6 μM, V~max~: 21 ± 5 pmol min^−1^) that are in a similar range as wild-type SERT (K~m~: 1.9 ± 0.3 μM, V~max~: 23 ± 1 pmol min^−1^) ([@bib13]; [@bib22]). The ts2-inactive variant (Tyr110Ala, Ile291Ala) ([@bib16]), by contrast, is unable to transport 5-HT but can be crystallized due to the stabilizing Tyr110Ala mutation ([@bib22]) and binds SSRIs with high-affinity. The ΔN72/ΔC13 SERT variant used for cryo-EM is otherwise wild-type SERT which has been truncated at the N- and C-termini ([Table 1](#table1){ref-type="table"}) and yet retains transport and ligand-binding activities ([@bib15]). Finally, the recombinant 8B6 Fab ([@bib13]; [@bib14]) was used to produce SERT-Fab complexes which were studied by X-ray crystallography and cryo-EM.

###### Expression constructs used in this study.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name              Expression construct                                                                                                                                                                                                                           Experiment
  ----------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  Wild-type SERT    Full-length human SERT with a C-terminal thrombin-GFP-StrepII-His~10~ tag.                                                                                                                                                                     \[^3^H\] 5-HT transport assays

  ∆N72/ ∆C13 SERT   Wild-type SERT modified by deletion of 72 residues on N-term and 13 residues on C-term                                                                                                                                                         Cryo-electron microscopy

  ts2-inactive      Full-length SERT with thrombin cleavage sites inserted after Gln76 and Thr618 and carrying the Tyr110Ala, Ile291Ala thermostabilizing mutations with additional mutations of surface-exposed cysteines Cys554, Cys580, and Cys622 to alanine   X-ray crystallography and\
                                                                                                                                                                                                                                                                   \[^3^H\] citalopram binding assays

  ts2-active        Full-length SERT with thrombin cleavage sites inserted after Gln76 and Thr618 and carrying the Ile291Ala, Thr439Ser thermostabilizing mutations with additional mutations of surface-exposed cysteines Cys554, Cys580, and Cys622 to alanine   \[^3^H\] citalopram binding assays

  Asn177 mutants    Asn177 mutated to either Val, Thr, or Gln in ts2-active background                                                                                                                                                                             \[^3^H\] citalopram binding assays
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We began by assessing the functional effects of paroxetine, Br-paroxetine, and I-paroxetine on SERT activity by measuring their inhibition of 5-HT transport and *S*-citalopram competition binding. We assayed the ability of the Br- and I-paroxetine derivatives to inhibit 5-HT transport in HEK293 cells expressing wild-type SERT, observing that upon substituting the 4-fluoro group with 4-bromo or 4-iodo groups, the potency of inhibition of 5-HT transport in wild-type SERT decreased significantly from 4 ± 1 for paroxetine to 40 ± 20 for Br-paroxetine and 180 ± 70 nM for I-paroxetine ([Figure 3a](#fig3){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). Next, we measured the binding of paroxetine, Br-paroxetine, and I-paroxetine to ts2-active and ts2-inactive SERT using *S*-citalopram competition binding assays, finding that the SERT variants employed in this study exhibited high-affinity for paroxetine and its derivatives ([Table 3](#table3){ref-type="table"}). A decrease in the binding affinity upon substituting the 4-fluoro group of paroxetine with 4-bromo or 4-iodo groups was observed in the competition binding assays. However, the difference in the binding affinities between paroxetine variants measured by the competition binding assay was not as pronounced as the difference in the inhibition potencies observed in the 5-HT transport assays ([Tables 2](#table2){ref-type="table"} and [3](#table3){ref-type="table"}). For example, the ts2-inactive (Tyr110Ala, Ile291Ala) variant employed in the previous ([@bib16]) and present x-ray studies exhibited a K~i~ of 0.17 ± 0.02 nM for paroxetine, 0.94 ± 0.01 nM for Br-paroxetine, and a further decrease in affinity to I-paroxetine (2.3 ± 0.1 nM). The ts2-active SERT variant binds with similar affinity to paroxetine and Br-paroxetine, and shows a 4--5 fold decrease in affinity to I-paroxetine ([Figure 3b](#fig3){ref-type="fig"}, [Table 3](#table3){ref-type="table"}).

![Inhibition of \[^3^H\]5-HT transport and \[^3^H\]citalopram binding by paroxetine and the Br- and I-derivatives.\
(**a**) 5-HT-transport of wild-type SERT and its inhibition by paroxetine, Br-, and I-paroxetine. Data are mean ± s.e.m. (n = 6). (**b**) Competition binding of paroxetine and its derivatives to ts2-inactive SERT. In panels **a** and **b**, paroxetine, Br-paroxetine, and I-paroxetine curves are shown as black, red, and blue lines, respectively. Data are mean ± s.e.m. (n = 6). (**c**) Competition binding of paroxetine to ts2-active (black), Asn177Val (red), Asn177Thr (green), and Asn177Gln (blue). Data are mean ± s.e.m. (n = 3). (**d**) Competition binding of Br-paroxetine. Data are mean ± s.e.m. (n = 3). (**e**) Competition binding of I-paroxetine. Data are mean ± s.e.m. (n = 3). The values associated with these experiments are reported in [Tables 2](#table2){ref-type="table"} and [3](#table3){ref-type="table"}.](elife-56427-fig3){#fig3}

###### Inhibition of 5-HT transport by paroxetine and its derivatives.

  Ligand          IC~50~
  --------------- ----------------
  Paroxetine      4 ± 1 nM
  Br-paroxetine   40 ± 20 nM
  I-paroxetine    0.18 ± 0.07 µM

###### Binding of paroxetine and its derivatives to SERT variants used in this study.

  SERT variant   K~i~ (nM)                   
  -------------- ------------- ------------- -----------
  ts2-inactive   0.17 ± 0.02   0.94 ± 0.01   2.3 ± 0.1
  ts2-active     0.31 ± 0.07   0.4 ± 0.2     1.7 ± 0.3
  Asn177Val      1.11 ± 0.04   5 ± 1         7.3 ± 0.9
  Asn177Thr      1.0 ± 0.1     5 ± 2         4.4 ± 0.4
  Asn177Gln      0.58 ± 0.07   4 ± 1         3.6 ± 0.4

In the x-ray structures of SERT, paroxetine was modeled in the ABC pose such that the benzodioxol group is in subsite B ([@bib16]; [@bib13]). A recent study suggested that binding affinity and potency to inhibit the transport of Br-paroxetine was only moderately affected upon mutating a non-conserved residue Ala169 to Asp in subsite B of SERT ([@bib45]; [Figure 1b](#fig1){ref-type="fig"}). We recently also identified a conserved residue, Asn177 in the subsite B, which upon mutation exhibited differential effects on the inhibitory potency of ibogaine and noribogaine ([@bib15]). To further probe the role of Asn177 in subsite B, we studied the binding of paroxetine and its derivatives to selected Asn177 mutants designed in the ts2-active background ([Figure 1b](#fig1){ref-type="fig"}). We observed that the affinity of paroxetine to ts2-active SERT decreased by three-fold when Asn177 is substituted with small non-polar or polar residues such as valine and threonine, while only a 2-fold change in K~i~ was observed for glutamine (Asn177Gln) ([Figure 3c](#fig3){ref-type="fig"}). In the case of Br-paroxetine, the Asn177 variants (K~i~ between 4 and 5 nM) display up to a 10--13 fold decrease in K~i~ when compared with ts2-active SERT (0.4 ± 0.2 nM) ([Figure 3d](#fig3){ref-type="fig"}, [Table 3](#table3){ref-type="table"}). The Asn177 variants show 2--4 fold decrease in affinity to I-paroxetine, with ts2-active SERT exhibiting a K~i~ of 1.7 ± 0.3 nM and the mutants a K~i~ of 4--7 nM. In the case of all three paroxetine variants, the reduction in affinity was the lowest for glutamine substitution. Irrespective of the SERT variant used, substitution of fluoro group with bromo or iodo group invariably decreased the affinity of paroxetine ([Figure 3e](#fig3){ref-type="fig"}, [Table 3](#table3){ref-type="table"}).

To define the binding poses of paroxetine and its analogues to SERT, we solved the structures of the ΔN72/ΔC13 and the ts2-inactive SERT variants complexed with Br- and I-paroxetine using single particle cryo-EM and X-ray crystallography ([Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}). We began by collecting cryo-EM data sets for ΔN72/ΔC13 SERT-8B6 Fab complexes with each ligand. The TM densities in all three reconstructions were well-defined and contiguous allowing for clear positioning of the main chain in an outward-open conformation ([Figure 4---figure supplements 3](#fig4s3){ref-type="fig"} and [4](#fig4s4){ref-type="fig"}). Large aromatic side-chains were well-resolved for all three complexes, also suggesting that the aromatic moieties of paroxetine and its analogues could be identified and positioned in our cryo-EM maps. In addition, the particle distribution and orientations of SERT-Fab complexes in presence of Br- and I-paroxetine were similar to paroxetine, allowing for uniform comparison between the maps.

The \~ 3.3 Å resolution map of the ΔN72/ΔC13 SERT-8B6 paroxetine complex allowed us to locate a density feature for the inhibitor at the central site ([Figure 4a](#fig4){ref-type="fig"}). The resolution of the Br- and I-paroxetine complexes was comparatively lower at \~ 4.1 Å and \~ 3.8 Å, respectively ([Table 4](#table4){ref-type="table"}, [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). Nevertheless, these ligands could also be modeled into the density at the central site with a correlation coefficient (CC) of 0.75 and 0.77, respectively ([Figure 4b--e](#fig4){ref-type="fig"}). To compare paroxetine in the ABC *vs.* the ACB pose, we flexibly modeled paroxetine in both poses at the central site followed by real space refinement. We observed that in the ACB pose, paroxetine could be positioned with a CC of 0.70 compared with 0.84 for the ABC pose suggesting that while ABC pose is clearly preferred under the conditions we tested, the possibility of an ACB pose cannot be excluded ([Figure 4---figure supplement 5a,b](#fig4s5){ref-type="fig"}). Based on the higher CC value, and the binding pose information from the ts2-inactive and ts3 SERT x-ray structures, the density in cryo-EM maps for paroxetine at the central site was interpreted to best accommodate ABC pose ([@bib16]; [@bib13]). We also compared the reconstructed complexes by calculating difference maps, attempting to identify features associated with the scattering of bromine and iodine at the central and allosteric sites. However, the resulting difference maps did not contain any interpretable difference densities and thus did not further assist in ligand modeling. In the cryo-EM maps, the maltose headgroup of a DDM molecule could also be visualized in the allosteric site with the detergent tail inserted between TMs 10, 11, and 12. In contrast, in the X-ray maps only the head group of the octyl-maltoside detergent could be modeled due to the weak density of the hydrocarbon chain.

![Structures of SERT-paroxetine complexes.\
(**a**) Cryo-EM reconstruction of SERT bound to paroxetine where the shape of the SERT-8B6 Fab complex and detergent micelle is shown in transparent light grey. The density of SERT is shown in dark blue with TM1 and TM6 colored in orange and yellow, respectively, and the density for paroxetine in green. The variable domain of the 8B6 Fab is colored in purple. Inset shows the density features at the central site of paroxetine. (**b**) Density feature at the central site of paroxetine. (**c**) Density feature at the central site of Br-paroxetine. (**d**) Density feature at the central site of I-paroxetine. (**e**) Comparison of the binding poses of paroxetine (grey), Br-paroxetine (green), and I-paroxetine (orange). (**f**) Anomalous difference electron density (blue) derived from Br-paroxetine, contoured at 5.2σ. g, Anomalous difference electron density (blue) derived from I-paroxetine, contoured at 4.3σ.](elife-56427-fig4){#fig4}

###### Cryo-EM data collection, refinement and validation statistics^a^.

  -----------------------------------------------------------------------------------
                                     \#1\             \#2\            \#3\
                                     (EMDB-21368)\    (EMDB-21369)\   (EMDB-21370)\
                                     (PDB 6VRH)\      (PDB 6VRK)      (PDB 6VRL)
                                     (EMPIAR-10380)                   
  ---------------------------------- ---------------- --------------- ---------------
  Data collection and processing                                      

  Magnification                      77,160           77,160          77,160

  Voltage (kV)                       300              300             300

  Electron exposure (e--/Å^2^)       54--60           54              54

  Defocus range (μm)                 −0.8 to −2.2     −0.8 to −2.2    −0.8 to −2.2

  Pixel size (Å)                     0.648            0.648           0.648

  Symmetry imposed                   C1               C1              C1

  Initial particle images (no.)      4,147,084        4,545,318       4,470,768

  Final particle images (no.)        420,373          503,993         414,091

  Map resolution (Å)\                3.3\             4.1\            3.8\
  FSC threshold                      0.143            0.143           0.143

  Map resolution range (Å)^†^        4.25--3.25       5.75--3.75      5.50--3.50

  Refinement                                                          

  Initial model used (PDB code)      6AWN             6VRH            6VRH

  Initial model CC\                  0.64\            0.70\           0.71\
  Model resolution (Å)^‡^\           3.7\             4.3\            4.1\
  FSC threshold                      0.5              0.5             0.5

  Model resolution range (Å)         25.9--3.3        33.0--4.1       29.6--4.2

  Map sharpening *B* factor (Å^2^)   −85              −174            −161

  Model composition\                 \                \               \
  Non-hydrogen atoms\                6143\            6142\           6142\
  Protein residues\                  764\             764\            764\
  Ligands (atoms)                    254              254             254

  *B* factors (Å^2^)\                \                \               \
  Protein\                           138\             138\            122\
  Ligand                             129              113             112

  R.m.s. deviations\                 \                \               \
  Bond lengths (Å)\                  0.002\           0.002\          0.002\
  Bond angles (°)                    0.48             0.59            0.54

  Validation\                        \                \               \
  Refined model CC\                  0.73\            0.74\           0.75\
  MolProbity score\                  1.86\            1.96\           1.88\
  Clashscore\                        9.67\            10.26\          10.59\
  Poor rotamers (%)                  0                0               0.00

  Ramachandran plot\                 \                \               \
  Favored (%)\                       94.84\           93.54\          95.12\
  Allowed (%)\                       5.16\            6.46\           4.88\
  Disallowed (%)                     0                0               0
  -----------------------------------------------------------------------------------

^a^Data set \#1 is the paroxetine reconstruction, \#2 is Br-paroxetine, \#3 I-paroxetine.

^†^Local resolution range.

^‡^Resolution at which FSC between map and model is 0.5.

We then explored the binding pose of paroxetine by growing crystals and collecting x-ray data of the ts2-inactive SERT-8B6 Fab complex with Br- and I-paroxetine ([Table 5](#table5){ref-type="table"}). Anomalous difference maps calculated from the previously determined ts2-inactive paroxetine structure (PDB ID: 6AWN) after refinement, showed clear densities for Br- and I- atoms of the paroxetine derivatives in subsite C ([Figure 4f,g](#fig4){ref-type="fig"}). No detectable anomalous peaks were observed in either subsite B or in the allosteric site and there were no other peaks in any other location above 2.5σ, suggesting that under these conditions, Br-paroxetine and I-paroxetine do not bind substantially in the ACB orientation or to the allosteric site. Next, we calculated isomorphous difference maps (F~o~-F~o~) using the ts2-inactive paroxetine dataset (PDB: 6AWN) and either the Br-paroxetine or I-paroxetine datasets. The F~o~(paroxetine)-F~o~(Br-paroxetine) map also revealed a difference peak in subsite C near the halogenated groups while no significant peaks were detected in subsite B ([Figure 4---figure supplement 6a](#fig4s6){ref-type="fig"}). Similarly, the F~o~(paroxetine)-F~o~(I-paroxetine) map also contained a difference peak which overlapped with the position of the halogen ([Figure 4---figure supplement 6b](#fig4s6){ref-type="fig"}) while the F~o~(Br-paroxetine)-F~o~(I-paroxetine) difference map did not contain any interpretable features, likely due to the low resolution of both datasets ([Figure 4---figure supplement 6c](#fig4s6){ref-type="fig"}).

###### X-ray data collection statistics.

  -----------------------------------------------------------------------------
                      Br-paroxetine\               I-paroxetine\
                      (PDB 6W2B)                   (PDB 6W2C)
  ------------------- ---------------------------- ----------------------------
  Data collection                                  

  Space group         C222~1~                      C222~1~

  Cell dimensions                                  

  *a*, *b*, *c* (Å)   128.0, 161.9, 139.7          127.7, 161.9, 140.8

  α, β, γ (°)         90, 90, 90                   90, 90, 90

  Resolution (Å)      20.45--4.69 (4.82--4.69)\*   25.98--6.12 (6.30--6.12)\*

  *R*~merge~          13.60 (339.3)                7.9 (292.9)

  *I* / σ*I*\         5.51 (0.49)\                 5.01 (0.32)\
  CC~1/2~             99.9 (16.5)                  99.8 (20.0)

  Completeness (%)    99.2 (100.0)                 92.6 (89.7)

  Redundancy          6.8 (6.2)                    1.8 (1.7)
  -----------------------------------------------------------------------------

^\*^Values in parentheses are for highest-resolution shell.

We next compared the cryo-EM structure of the SERT-paroxetine complex to the X-ray structure of the ts3 SERT paroxetine complex. Overall comparison of the transporter revealed only minor variation between structures solved by each method, with a Cα root-mean-square-deviation (RMSD) of 0.68 Å. The most significant differences between the cryo-EM and the X-ray structures were found at the extracellular and intracellular sites of TM12 and also in EL2, while the core of the transporter (TM1-10) was largely unchanged ([Figure 5a](#fig5){ref-type="fig"}). These changes can largely be explained on the basis of a crystal packing interface formed by TM12 and a highly flexible EL2 that is bound to the 8B6 Fab. We also compared central site residues involved in paroxetine binding, finding that the best fit to the cryo-EM density revealed only minor differences in the side-chains of Asp98, Tyr176, and Phe335 when compared to the x-ray structure (all atom RMSD: 0.91 Å) ([Figure 5b](#fig5){ref-type="fig"}). Finally, we compared the cryo-EM structures of the SERT 15B8 Fab/8B6 scFv paroxetine complex (PDB: 6DZW) to the SERT 8B6 Fab paroxetine complex to understand if these antibodies induce changes in transporter structure. Here we found that the most significant differences occurred in the extracellular domain and involved localized regions of EL2 and EL4 that interact with the antibody ([Figure 5c](#fig5){ref-type="fig"}). The transporter core was largely unchanged, with the only other significant differences being found in EL6, TM12, and IL4.

![Comparison of the X-ray and cryo-EM structures of the SERT-paroxetine complex.\
(**a**) Superposition of the x-ray ts3-SERT-8B6 paroxetine structure (PDB: 5I6X) with the SERT-8B6 paroxetine complex determined by cryo-EM. The root-mean-square-deviations (RMSD) for Cα positions were plotted onto the cryo-EM SERT-8B6 paroxetine structure. (**b**) Comparison of the central binding site of the x-ray (grey) and cryo-EM (green) paroxetine structures. (**c**) The structure of the ts2-inactive SERT-8B6 scFv/15B8 Fab paroxetine (cryo-EM, 6DZW), ts2-inactive SERT-8B6 Fab paroxetine (x-ray, 6AWN), and the SERT-8B6 paroxetine (cryo-EM, this work) complexes were superposed onto the ts3 SERT-8B6 paroxetine complex (x-ray, 5I6X) as a reference. The RMSD for Cα positions were calculated for each structure in comparison with the reference. Regions with RMSD \> 3.0 Å are shown boxed in red.](elife-56427-fig5){#fig5}

Discussion {#s3}
==========

The binding of paroxetine to SERT has been extensively debated ([@bib16]; [@bib13]; [@bib1]; [@bib18]; [@bib45]). The first X-ray structure of the ts3-SERT variant demonstrated that the binding pose is such that the piperidine, benzodioxol, and fluorophenyl groups occupy subsites A, B, and C respectively, in the ABC pose ([@bib13]; [Figure 1b](#fig1){ref-type="fig"}). Competition binding experiments using a variant of SERT containing a central binding site that has been genetically engineered to possess photo-cross-linking amino acids corroborated that paroxetine binds in a fashion which is similar to that observed in crystal structure ([@bib16]; [@bib13]), where the fluorophenyl group is in proximity to Val501 ([@bib39]). However, computational docking experiments using wild-type SERT predicted that the position of benzodioxol and fluorophenyl groups of paroxetine are 'flipped', with paroxetine occupying an ACB pose ([@bib18]; [Figure 1c](#fig1){ref-type="fig"}). Subsequent studies involving wild-type and mutant SERT variants, that include modeling, mutagenesis, and Br-paroxetine docking experiments suggested that paroxetine could bind in both ABC and ACB poses. These studies also suggested that bromination of paroxetine and certain mutations near the central site, such as Ala169Asp, favored ABC pose ([@bib1]; [@bib45]). Hence, the authors in these studies hypothesized that the ABC pose observed in the crystal structure could be because of the crystallization conditions and thermostabilizing mutations.

One of the thermostabilizing mutations in ts3-SERT, Thr439Ser, is near the central binding site and Thr439 participates in a hydrogen bonding network in subsite B that, in turn, includes the dioxol group of paroxetine. To probe the role of the Thr439Ser mutation in modulating the binding pose of paroxetine, we solved the X-ray structure of ts2-inactive (Tyr110Ala, Ile291Ala) SERT, wherein the residue at position 439 was the wild-type threonine. Paroxetine could be modeled in the ABC pose in the X-ray structure of ts2-inactive SERT ([@bib16]). MD simulations of ts2-inactive SERT suggested that the Thr439Ser mutation weakens the Na2 site. Furthermore, MD simulations and binding and uptake kinetics experiments using wild-type SERT in presence of paroxetine and a variant of paroxetine where in the 4-fluoro group is substituted with 4-bromo group suggested that the paroxetine binding pose in SERT could be ambiguous because of the pseudo symmetry of the paroxetine molecule. It was noted that paroxetine could occupy both ABC and ACB poses with almost equivalent preference. Upon substituting the 4-fluoro with a bulkier 4-bromo group, the ABC pose was favored ([@bib1]; [@bib45]).

Structural studies of SERT in complex with paroxetine and its analogues were thus required to resolve the uncertainty in paroxetine binding pose at the central site. Previously, we had demonstrated that cryo-EM can be used to define the position of ligands at the central site of SERT ([@bib15]). Here, we employed a similar methodology using the ΔN72/ΔC13 SERT variant complexed with 8B6 Fab to study binding of paroxetine at the central site. The density feature of paroxetine in the cryo-EM map at \~ 3.3 Å clearly resolved the larger benzodioxol and smaller fluorophenyl groups in subsite B and C, respectively ([Figure 4b](#fig4){ref-type="fig"}). Though this reconstruction suggests that paroxetine binds in the ABC pose, we also considered the possibility that the inhibitor density feature may represent an average of the ABC and ACB poses. We expected that if Br- and I-paroxetine were suitable surrogates for paroxetine, their binding pose would be unaffected by their reduced electronegativity and the size of the halogenated groups and therefore that they would also be associated with a comparable density feature at this site, as demonstrated by our cryo-EM maps. To further explore if there was a fraction of Br- or I-paroxetine in the ACB pose, we examined the position of the Br- or I- atoms at the central site by X-ray crystallography. If Br- and I-paroxetine were to bind in both the ABC or ACB poses, we expected to observe two anomalous peaks in our x-ray maps in subsites B and C; for both ligands, however, only a single detectable peak was observed in subsite C ([Figure 4f,g](#fig4){ref-type="fig"}). Thus, our direct biophysical observations reveal that under the conditions that we tested the ABC pose of paroxetine is preferred over the the ACB pose.

Paroxetine is stabilized at the central binding site by aromatic, ionic, non-ionic, hydrogen bonding, and cation-π interactions ([@bib16]). In the ABC pose, the amine of the piperidine ring of paroxetine binds with Asp98 (3.5 Å) and also makes a cation-π interaction with Tyr95 of subsite A ([Figure 4a](#fig4){ref-type="fig"}). The benzodioxol group of paroxetine, a catechol-like entity, occupies a position in subsite B which is similar to the binding of catechol derivative groups of sertraline and 3,4-dichlorophenethylamine in SERT ([@bib16]) and dDAT ([@bib48]) structures, respectively. In subsite B, the ring of Tyr176 makes an aromatic interaction with the benzodioxol while the hydrogen-bonding network in subsite B formed by Asn177, Thr439, backbone carbonyl oxygens, and amides are likely responsible for stabilization of the dioxol. The side-chain of Ile172 inserts between the benzodioxol and fluorophenyl, while the rings of Phe341 and Phe335 stack on either side of the fluorophenyl, 'sandwiching' it within subsite C. The halogen group of paroxetine and its analogues reside adjacent to the side-chain of Thr497 (4.0 Å), which may act to stabilize these groups through hydrogen bonding ([Figure 4a](#fig4){ref-type="fig"}). The larger atomic radius, the longer length of the carbon-halogen bond, and the difference in electronegativity of bromine (radius: 1.85 Å, bond-length: 1.92 Å, electronegativity: 2.96) and iodine (radius: 1.98 Å, bond-length: 2.14 Å, electronegativity: 2.66) relative to fluorine (radius: 1.47 Å, bond-length: 1.35 Å, electronegativity: 3.98) would explain why the fluorine analogue binds with greater affinity than Br-paroxetine and I-paroxetine.

We also explored the effect of conservative and non-conservative mutations in subsite B of SERT at Asn177 ([Figure 3](#fig3){ref-type="fig"}). Asn177 participates in a hydrogen-bond network with the hydroxyl group of noribogaine and with the dioxol of paroxetine. However, this network of interactions is also important for binding halogenated inhibitors in subsite B, as in the case for *S*-citalopram, fluvoxamine, and sertraline. All the mutants that we tested at Asn177 resulted in a loss of binding affinity to paroxetine and its analogues. Furthermore, the Ala169Asp mutation in subsite B ([@bib45]; [Figure 1b,c](#fig1){ref-type="fig"}) also reduced paroxetine inhibition and binding, likely also disrupting these interactions. Although the effects were less severe when compared to paroxetine, Br-paroxetine binding and inhibition was also reduced for Ala169Asp ([@bib45]). Thus, these mutations highlight the importance of subsite B interactions in paroxetine binding but they cannot be used to demonstrate the inhibitor pose because, in the ABC or ACB poses, either the dioxol or fluorine of paroxetine could act as a hydrogen-bond acceptor in subsite B.

Using a combination of chemical biology, cryo-EM, and X-ray crystallography we observed that under the conditions that we studied, the SSRI paroxetine preferably occupies the ABC pose at the central site, where it is involved in numerous interactions. However, the data presented in the manuscript does not completely exclude the possibility of an ACB pose at the central site. Our studies of the mechanism of paroxetine binding to SERT provide a robust framework for the design of experiments to identify new highly specific small-molecule SERT inhibitors.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                             Source or\                                                      Identifiers                                                    Additional\
  (species) or\                                                                                 reference                                                                                                                      information
  resource                                                                                                                                                                                                                     
  ------------------------------------- ------------------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Gene (*Homo sapiens*)                 Human serotonin transporter                             cDNA                                                            NCBI Reference Sequence: NP_001036.1                           Dr. Randy D. Blakely (Florida Atlantic university brain institute)

  Cell line (*Homo sapiens*)            HEK293S GnTI-                                           ATCC                                                            Cat \# ATCC CRL-3022                                           Used for expression of SERT (PMID:[27929454](https://www.ncbi.nlm.nih.gov/pubmed/27929454))

  Cell line (*Spodoptera frugiperda*)   SF9 cells                                               ATCC                                                            Cat \# ATCC CRL-1711                                           Used in production of baculovirus for transduction, and SERT antibodies (PMID:[27929454](https://www.ncbi.nlm.nih.gov/pubmed/27929454))

  Antibody                              Mouse monoclonal. Isotype IgG2a, kappa                  OHSU VGTI, Monoclonal Antibody Core                                                                                            8B6

  Transfected construct (human)         pEG BacMam                                              Gouaux lab                                                                                                                     PMID:[25299155](https://www.ncbi.nlm.nih.gov/pubmed/25299155)

  Affinity chromatography resin         Strep-Tactin Superflow high capacity resin              Iba life sciences                                               Cat\#2-1208-500                                                

  Chemical compound, drug               n-dodecyl-β-D-maltoside                                 Anatrace                                                        Cat \# D310                                                    Detergent

  Chemical compound, drug               n-octyl β-D-maltoside                                   Anatrace                                                        Cat \# O310                                                    Detergent

  Chemical compound, drug               fluorinated octyl-maltoside                             Anatrace                                                        Cat \# O310F                                                   Detergent

  Chemical compound, drug               Cholesteryl Hemisuccinate                               Anatrace                                                        Cat \# CH210                                                   Lipid

  Chemical compound, drug               1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine        Anatrace                                                        Cat \# P516                                                    Lipid

  Chemical compound, drug               1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine   Anatrace                                                        Cat \# P416                                                    Lipid

  Chemical compound, drug               1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol       Anatrace                                                        Cat \# P616                                                    Lipid

  Chemical compound, drug               Paroxetine hydrochloride hemihydrate                    Sigma                                                           Cat \# P9623                                                   Inhibitor

  Chemical compound, drug               \[^3^H\]5-HT                                            PerkinElmer                                                     Cat \# NET1167250UC                                            Radiolabeled substrate

  Chemical compound, drug               \[^3^H\]citalopram                                      PerkinElmer                                                     Cat \# NET1039250UC                                            Radiolabeled inhibitor

  Software, algorithm                   XDS                                                     PMID:[20124692](https://www.ncbi.nlm.nih.gov/pubmed/20124692)   RRID:[SCR_015652](https://scicrunch.org/resolver/SCR_015652)   <http://xds.mpimf-heidelberg.mpg.de/>

  Software, algorithm                   Phaser                                                  PMID:[24189240](https://www.ncbi.nlm.nih.gov/pubmed/24189240)   RRID:[SCR_014219](https://scicrunch.org/resolver/SCR_014219)   <https://www.phaser.cimr.cam.ac.uk/index.php/Phaser_Crystallographic_Software>

  Software, algorithm                   Phenix                                                  PMID:[22505256](https://www.ncbi.nlm.nih.gov/pubmed/22505256)   RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)   <https://www.phenix-online.org/>

  Software, algorithm                   SerialEM                                                PMID:[16182563](https://www.ncbi.nlm.nih.gov/pubmed/16182563)   RRID:[SCR_017293](https://scicrunch.org/resolver/SCR_017293)   <http://bio3d.colorado.edu/SerialEM>

  Software, algorithm                   MotionCor2                                              PMID:[28250466](https://www.ncbi.nlm.nih.gov/pubmed/28250466)   RRID:[SCR_016499](https://scicrunch.org/resolver/SCR_016499)   <http://msg.ucsf.edu/em/software/motioncor2.html>

  Software, algorithm                   CTFFIND4                                                PMID:[26278980](https://www.ncbi.nlm.nih.gov/pubmed/26278980)   RRID:[SCR_016732](https://scicrunch.org/resolver/SCR_016732)   <https://grigoriefflab.umassmed.edu/ctffind4>

  Software, algorithm                   DoG-Picker                                              PMID:[19374019](https://www.ncbi.nlm.nih.gov/pubmed/19374019)                                                                  <http://emg.nysbc.org/redmine/projects/software/wiki/DoGpicker>

  Software, algorithm                   cryoSPARC                                               PMID:[28165473](https://www.ncbi.nlm.nih.gov/pubmed/28165473)   RRID:[SCR_016501](https://scicrunch.org/resolver/SCR_016501)   <https://cryosparc.com/>

  Software, algorithm                   RELION                                                  PMID:[23000701](https://www.ncbi.nlm.nih.gov/pubmed/23000701)   RRID:[SCR_016274](https://scicrunch.org/resolver/SCR_016274)   <http://www2.mrc-lmb.cam.ac.uk/relion>

  Software, algorithm                   cisTEM                                                  PMID:[29513216](https://www.ncbi.nlm.nih.gov/pubmed/29513216)   RRID:[SCR_016502](https://scicrunch.org/resolver/SCR_016502)   <https://cistem.org/>

  Software, algorithm                   UCSF-Chimera                                            PMID:[15264254](https://www.ncbi.nlm.nih.gov/pubmed/15264254)   RRID:[SCR_004097](https://scicrunch.org/resolver/SCR_004097)   <https://www.cgl.ucsf.edu/chimera/>

  Software, algorithm                   Coot                                                    PMID:[15572765](https://www.ncbi.nlm.nih.gov/pubmed/15572765)   RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)   <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot>

  Software, algorithm                   MolProbity                                              PMID:[20057044](https://www.ncbi.nlm.nih.gov/pubmed/20057044)   RRID:[SCR_014226](https://scicrunch.org/resolver/SCR_014226)   <http://molprobity.biochem.duke.edu/>

  Other                                 R 2/2 200 mesh Au holey carbon grids                    Electron Microscopy Sciences                                    Cat \# Q2100AR2                                                Cryo-EM grids

  Other                                 Copper HIS-Tag YSI                                      PerkinElmer                                                     Cat \# RPNQ0096                                                SPA beads
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SERT expression and purification {#s4-1}
--------------------------------

The human SERT constructs used in this study were the wild-type, the N- and C-terminally truncated wild-type (ΔN72/ΔC13), ts2-inactive (Tyr110Ala, Ile291Ala), and ts2-active (Ile291Ala, Thr439Ser) ([@bib16]; [@bib13]; [@bib22]; [@bib15]; [@bib14]) proteins ([Table 1](#table1){ref-type="table"}). The Asn177 mutants were generated in the ts2-active background. The expression and purification of SERT was carried out as previously described with minor modifications ([@bib16]; [@bib13]; [@bib15]; [@bib14]), as described below. All SERT constructs were cloned into BacMam vector system to be expressed as C-terminal GFP fusion using baculovirus-mediated transduction of HEK293S GnTI^-^ cells. Cells were solubilized in 20 mM Tris pH 8 with 150 mM NaCl, containing 20 mM n-dodecyl-β-D-maltoside (DDM) and 2.5 mM cholesteryl hemisuccinate (CHS), followed by purification using Strep-Tactin affinity chromatography in 20 mM Tris pH 8 with 100 mM NaCl (TBS), 1 mM DDM, and 0.2 mM CHS.

For cryo-EM of the ΔN72/ΔC13 SERT, 1 mM 5-HT was added during solubilization and affinity purification to stabilize SERT. GFP was cleaved from SERT by digestion with thrombin and the SERT-8B6 complex was made as described in the previous paragraph. The complex was separated from free Fab and GFP by SEC in TBS containing 1 mM DDM and 0.2 mM CHS, and the peak fractions were concentrated to 4 mg/ml followed by addition of either 200 μM paroxetine, Br-paroxetine or I-paroxetine.

For crystallization, no ligands were added during purification of ts2-inactive SERT, and 5% glycerol and 25 μM lipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol at a molar ratio of 1:1:1) were included in all the purification buffers. Following affinity purification, the fusion protein was digested by thrombin and EndoH and combined with recombinant 8B6 Fab at a molar ratio of 1:1.2. The SERT-8B6 complex was isolated by size-exclusion chromatography (SEC) on a Superdex 200 column in TBS containing 40 mM n-octyl β-D-maltoside, 0.5 mM CHS. The SERT-8B6 Fab complex was concentrated to 2 mg/ml and 1 μM 8B6 Fab and 50 μM Br-paroxetine or I-paroxetine was added prior to crystallization.

Synthesis of Br- and I-paroxetine {#s4-2}
---------------------------------

All reactions were carried out under an inert atmosphere (argon) with flame-dried glassware using standard techniques, unless otherwise specified. Anhydrous solvents were obtained by filtration through drying columns (THF, MeCN, CH~2~Cl~2~ and DMF) or used as supplied (α,α,α-trifluorotoluene). Reactions in sealed tubes were run using Biotage microwave vials (2--5 ml or 10--20 ml recommended volumes). Aluminum caps equipped with molded butyl/PTFE septa were used for reactions in α,α,α-trifluorotoluene and toluene. Simple butyl septa were used for reactions in other solvents. Chromatographic purification was performed using 230--400 mesh silica with the indicated solvent system according to standard techniques. Analytical thin-layer chromatography (TLC) was performed on precoated, glass-backed silica gel plates. Visualization of the developed chromatogram was performed by UV absorbance (254 nm) and/or stained with a ninhydrin solution in ethanol. HPLC analyses were carried out on an Agilent 1260 Infinity Series system, employing Daicel Chiracel columns, under the indicated conditions. The high-resolution mass spectrometry (HRMS) analyses were performed using electrospray ion source (ESI). ESI was performed using a Waters LCT Premier equipped with an ESI source operated either in positive or negative ion mode. The software used was MassLynx 4.1; this software does not account for the electron and all the calibrations/references are calculated accordingly, that is \[M+H\]^+^ is detected and the mass is calibrated to output \[M+H\]. Melting points are uncorrected. Infrared spectra (FTIR) were recorded in reciprocal centimeters (cm^--1^).

Nuclear magnetic resonance spectra were recorded on 400 or 500 MHz spectrometers. The frequency used to record the NMR spectra is given in each assignment and spectrum (^1^H NMR at 400 or 500 MHz; ^13^C NMR at 101 MHz or 126 MHz). Chemical shifts for ^1^H NMR spectra were recorded in parts per million from tetramethylsilane with the residual protonated solvent resonance as the internal standard (CHCl~3~: δ 7.27 ppm, (CD~2~H)~2~SO: δ 2.50 ppm, CD~2~HOD: δ 3.31 ppm). Data was reported as follows: chemical shift (multiplicity \[s = singlet, d = doublet, t = triplet, m = multiplet and br = broad\], coupling constant, integration and assignment). *J* values are reported in Hz. All multiplet signals were quoted over a chemical shift range. ^13^C NMR spectra were recorded with complete proton decoupling. Chemical shifts were reported in parts per million from tetramethylsilane with the solvent resonance as the internal standard (^13^CDCl~3~: δ 77.0 ppm, (^13^CD~3~)~2~SO: δ 39.5 ppm, ^13^CD~3~OD: δ 49.0 ppm). Assignments of ^1^H and ^13^C spectra, as well as *cis-* or *trans*-configuration, were based upon the analysis of δ and *J* values, analogy with previously reported compounds ([@bib4]), as well as DEPT, COSY and HSQC experiments, where appropriate. All Boc containing compounds appeared as a mixture of rotamers in the NMR spectra at room temperature. In some cases, NMR experiments for these compounds were carried out at 373 K to coalesce the signals, which is indicated in parentheses where appropriate. For NMR analysis performed at room temperature, 2D NMR experiments (COSY and HSQC) are also presented when useful for the assignments. Observed optical rotation (α') was measured at the indicated temperature (T °C) and values were converted to the corresponding specific rotations $\left\lbrack \alpha \right\rbrack_{D}^{T}$ in deg cm^2^g^--1^, concentration (*c*) in g per 100 mL. Full details of the synthetic route, using enantiopure and racemic substrates are provided in Appendix 1, and NMR spectra of all reaction intermediates, 2 and 3, and HPLC analysis are cataloged in [Supplementary files 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}.

Crystallization {#s4-3}
---------------

Crystals of ts2-inactive SERT-8B6 Fab complex were grown by hanging-drop vapor diffusion at 4°C at a ratio of 2:1 (v/v) protein:reservoir. Br-paroxetine crystals were grown using reservoir solution containing 50 mM Tris pH 8.5, 20 mM Na~2~(SO4), 20 mM LiCl~2~, 36% PEG 400, and 0.5% 6-aminohexanoic acid. I-paroxetine crystals were grown using a reservoir solution containing 100 mM HEPES pH 7.5, 40 mM MgCl~2~, and 32% PEG 400.

X-ray data collection {#s4-4}
---------------------

Crystals were harvested and flash cooled in liquid nitrogen. Data was collected at the Advanced Photon Source (Argonne National Laboratory, beamline 24-ID-C). Data for Br-paroxetine was collected at a wavelength of 0.91840 Å and at 1.37760 Å for I-paroxetine.

Anomalous difference maps {#s4-5}
-------------------------

X-ray data sets were processed with XDS ([@bib26]); Friedel pairs were allowed to have different intensities. Molecular replacement was performed with coordinates from the previously determined ts2-inactive SERT-paroxetine structure (Protein Data Bank (PDB) code: 6AWN) ([@bib16]) using PHASER ([@bib8]). B-factors were refined using PHENIX ([@bib2]) followed by generating anomalous difference maps using the phases derived from the higher resolution structures. To maximize the signal-to-noise ratio of the Br-paroxetine anomalous difference density, the high-resolution phases were blurred with a B-factor of 500 with a high-resolution cutoff of 5.5 Å. Using these optimized parameters for the Fourier analysis of the Br-paroxetine diffraction data, we obtained an anomalous map with the largest difference peak being present at 6.0σ and the noise level estimated at \~ 2.5σ. To maximize the signal-noise-ratio of the I-paroxetine anomalous difference density, a high-resolution and low-resolution cutoff of 6.3 and 30 Å was applied during the generation of the anomalous maps. Using these optimized parameters for the Fourier analysis of the I-paroxetine diffraction data, we obtained an anomalous map with the largest difference peak being present at 4.5σ and the noise level estimated at \~ 2.5σ.

F~o~-F~o~ isomorphous difference maps {#s4-6}
-------------------------------------

Isomorphous difference (F~o~-F~o~) maps were calculated in PHENIX by analyzing isomorphous pairs of crystals. Difference maps were calculated using the previously determined ts2-inactive SERT-paroxetine dataset and PDB (6AWN) for phasing. High- and low-resolution cutoffs of 6.0 and 30.0 Å were applied for the F~o~(paroxetine)- F~o~(Br-paroxetine) map and cutoffs of 6.3 and 30.0 Å were used for the F~o~(paroxetine)- F~o~(I-paroxetine) and F~o~(Br-paroxetine)- F~o~(I-paroxetine) maps.

Cryo-EM grid preparation {#s4-7}
------------------------

To promote the inclusion of particles in thin ice, 100 μM fluorinated octyl-maltoside (final concentration) from a 10 mM stock was added to SERT-8B6 complexes immediately prior to vitrification. Quantifoil holey carbon gold grids, 2.0/2.0 μm, size/hole space, 200 mesh) were glow discharged for 60 s at 15 mA. SERT-8B6 Fab complex (2.5 μl) was applied to the grid followed by blotting for 2 s in the vitrobot and plunging into liquid ethane cooled by liquid N~2~.

Cryo-EM data collection and processing {#s4-8}
--------------------------------------

Images were acquired using the automated program SerialEM ([@bib31]) on a FEI Titan Krios transmission electron microscope, operating at 300 keV and equipped with a Gatan Image Filter with the slit width set to 20 eV. A Gatan K3 direct electron detector was used to record movies in super-resolution counting mode with a binned pixel size of 0.648 Å per pixel. The defocus values ranged from −0.8 to −2.2 μm. Exposures of 1.0--1.5 s were dose fractioned into 40 frames, resulting in a total dose of 54--60 *e*^−^ Å^−2^. Movies were corrected for beam-induced motion using MotionCor2 ([@bib53]) with 5 × 5 patching. The contrast transfer function (CTF) parameters for each micrograph was determined using ctffind4 ([@bib41]) and particles were picked either using DoG-Picker ([@bib46]) or blob-based picking in cryoSPARC ([@bib38]). DoG or cryoSPARC picked particles were independently subjected to 3D classification against a low-resolution volume of the SERT-8B6 complex. After sorting, the DoG and cryoSPARC picked particles were combined in RELION ([@bib44]) and the duplicate picks were removed (particle picks that are less than 100 Å of one another were considered duplicates). Combined particles were further sorted using reference-free 2D classification in cryoSPARC, followed by refinement in RELION and further 3D classification. Particles were then re-extracted (box size 400, 0.648 Å per pixel) and subjected to non-uniform refinement in cryoSPARC. Local refinement was then performed in *cis*TEM ([@bib21]) with a mask that excludes the micelle and Fab constant domain to remove low-resolution features. The high-resolution refinement limit was incrementally increased while maintaining a correlation of 0.95 or better until no improvement in map quality was observed. The resolution of the reconstructions was accessed using the Fourier shell correlation (FSC) criterion and a threshold of 0.143 ([@bib42]). Map sharpening was performed using local sharpening in PHENIX.

Cryo-EM model building and refinement {#s4-9}
-------------------------------------

A starting model was generated by fitting the X-ray structure of SERT-8B6 Fab paroxetine complex (PDB code: 6AWN) into the cryo-EM reconstruction in Chimera ([@bib36]). Several rounds of manual adjustment and rebuilding were performed in Coot ([@bib19]), followed by real space refinement in PHENIX. For cross-validation, the FSC curve between the refined model and half maps was calculated and compared to prevent overfitting. Molprobity was used to evaluate the stereochemistry and geometry of the structures ([@bib10]).

Radioligand binding and uptake assays {#s4-10}
-------------------------------------

Competition binding experiments were performed using scintillation proximity assays (SPA) ([@bib22]; [@bib14]). The assays contained \~ 10 nM SERT, 0.5 mg/ml Cu-Ysi beads in TBS with 1 mM DDM, 0.2 mM CHS, and 10 nM \[^3^H\]citalopram and 0.01 nM--1 mM of the cold competitors. Experiments were measured in triplicate. The error bars for each data point represent the s.e.m. Ki values were determined with the Cheng--Prusoff equation ([@bib11]) in GraphPad Prism. Uptake was measured as described previously in 96-well plates with \[^3^H\]5-HT diluted 1:100 with unlabeled 5-HT. After 24 hr, cells were washed into uptake buffer (25 mM HEPES-Tris, pH 7.0, 130 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl~2~, 1.2 mM MgSO~4~, 1 mM ascorbic acid and 5 mM glucose) containing 0.001--10,000 nM of the inhibitor. \[^3^H\]5-HT was added to the cells and uptake was stopped by washing cells rapidly three times with uptake buffer. Cells were solubilized with 1% Triton-X100, followed by the addition of 200 μl of scintillation fluid to each well. The amount of labelled 5-HT was measured using a MicroBeta scintillation counter. Data were fit to a sigmoidal dose-response curve.
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###### HPLC Traces for Racemic, Scalemic and Enantioenriched Br-Piperidine Derivatives (±)-S2a, (±)-S3a, (+)-6a, (+)-7a, (--)-S3a, (--)-8a and (+)-S4a.

###### NMR Spectra for Novel Compounds.

Data availability {#s7}
=================

The coordinates and associated volumes for the cryo-EM reconstruction of SERT 8B6 Fab paroxetine, Br-paroxetine, and I-paroxetine datasets have been deposited in the PDB (<https://www.rcsb.org/>) and Electron Microscopy Data Bank (EMDB; <https://www.ebi.ac.uk/pdbe/emdb/>) under the accession codes 6VRH and 21368, 6VRK and 21369, and 6VRL and 21370, respectively. The half maps for each dataset have also been deposited in the EMDB (<https://www.ebi.ac.uk/pdbe/emdb/>). The x-ray coordinates for Br-paroxetine and I-paroxetine have been deposited in the PDB (<https://www.rcsb.org/>) under accession codes 6W2B and 6W2C, respectively.

The following datasets were generated:

ColemanJANavratnaVYangD2020Cryo-EM structure of the wild-type human serotonin transporter complexed with paroxetine and 8B6 FabRCSB Protein Data Bank6VRH

ColemanJANavratnaVYangD2020Cryo-EM structure of the wild-type human serotonin transporter complexed with paroxetine and 8B6 FabElectron Microscopy Data Bank21368

ColemanJANavratnaVYangD2020Cryo-EM structure of the wild-type human serotonin transporter complexed with Br-paroxetine and 8B6 FabRCSB Protein Data Bank6VRK

ColemanJANavratnaVYangD2020Cryo-EM structure of the wild-type human serotonin transporter complexed with Br-paroxetine and 8B6 FabElectron Microscopy Data Bank21369

ColemanJANavratnaVYangD2020Cryo-EM structure of the wild-type human serotonin transporter complexed with I-paroxetine and 8B6 FabRCSB Protein Data Bank6VRL

ColemanJANavratnaVYangD2020Cryo-EM structure of the wild-type human serotonin transporter complexed with I-paroxetine and 8B6 FabElectron Microscopy Data Bank21370

ColemanJANavratnaVYangD2020Anomalous bromine signal reveals the position of Br-paroxetine complexed with the serotonin transporter at the central siteRCSB Protein Data Bank6W2B

ColemanJANavratnaVYangD2020Anomalous iodine signal reveals the position of I-paroxetine complexed with the serotonin transporter at the central siteRCSB Protein Data Bank6W2C

Synthesis of paroxetine analogues {#s8}
=================================

Reagents {#s8-1}
--------

### Commercial reagents were used as supplied or purified by standard techniques where necessary {#s8-1-1}

Pd(OAc)~2~, 8-Aminoquinoline, 1-(*tert*-butoxycarbonyl)piperidine-3-carboxylic acid and (*R*)−1-(*tert*-butoxycarbonyl)piperidine-3-carboxylic acid were purchased from Fluorochem Ltd and used as supplied.

PivOH and α,α,α-trifluorotoluene were purchased from Sigma-Aldrich Company Ltd and used as supplied.

K~2~CO~3~ was purchased from Sigma-Aldrich Company Ltd and flame-dried before use as part of reaction set-up.

Purity: Pd(OAc)~2~,\>98%; PivOH, 99%; K~2~CO~3~,≥98% (powder, --325 mesh), α,α,α-trifluorotoluene, anhydrous,≥99%.

Racemic and enantioenriched substrates *tert*-butyl (±)−3-(quinoline-8-ylcarbamoyl)piperidine-1-carboxylate ((±)-S1) and *tert*-butyl (--)-(*R*)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((*--*)−5) were prepared by amide coupling of commercially available 8-aminoquinoline and the corresponding carboxylic acid (1-(*tert*-butoxycarbonyl)piperidine-3-carboxylic acid and (*R*)−1-(*tert*-butoxycarbonyl)piperidine-3-carboxylic acid, respectively) according to our previously reported procedures ([@bib4]).

Structures of additional compounds in appendix 1 {#s9}
================================================

![Full Synthetic Route to Racemic and Enantioenriched Br-Piperidine Derivatives (±)-S2a, (±)-S3a, (+)−6a, (+)−7a, (--)-S3a, (--)−8a, (+)-S4a, (--)−9a and Br-(--)-paroxetine 2.\
In order to evaluate the enantiomeric excess of key intermediates (+)−6a and (+)−7a by chiral HPLC, the C--H arylation with 4-bromo iodobenzene was performed on both racemic ((±)-S1) and enantioenriched (--)−5 piperidine amide substrates ([Scheme 1](#app1scheme1){ref-type="fig"}). The racemic synthesis was performed on a 0.5 mmol scale according to our previously reported protocol, ([@bib4]) and afforded *cis-*arylated derivatives (±)-S2a in 34% ([Scheme 1a](#app1scheme1){ref-type="fig"}). A minor *trans*-functionalized product (±)-S3a, formed via a *trans*-palladacycle, ([@bib4]) was also isolated in 14%. C--H Arylation of enantioenriched substrate (--)−5 proceed smoothly on a 4.0 mmol scale, and *cis-* and *trans-*piperidine products (+)−6a and (--)-S3a were isolated as single enantiomers in very similar yields (Scheme S1b). Subsequent treatment of enantiopure *cis-*derivative (+)−6a with DBU at 100°C afforded the *trans-*diastereomer as the right-handed enantiomer (+)−7a in 94% yield.](elife-56427-app1-fig1){#app1chem1}

![Synthetic sequence, including the Pd-catalyzed C(4)--H arylation step, to access racemic and enantioenriched *cis-* and *trans-*piperidine amide derivatives (±)-S2a, (±)-S3a, (+)−6a, (+)−7a and (--)-S3a.\
(**a**) C--H Arylation conditions: (±)-S1 (0.5 mmol, one equiv) Ph-CF~3~ (500 μL, 1 M). (**b**) C--H Arylation conditions: (--)−5 (4.0 mmol, one equiv), Ph-CF~3~ (2.0 mL, 2 M). The enantiomeric excess of alcohol intermediates (+)-S4a and (--)−8a was evaluated after aminoquinoline removal on both enantiomeric *trans-*derivatives (--)-S3a and (+)−7a ([Scheme 2](#app1scheme2){ref-type="fig"}). No undesired debromination was observed for the reductive aminoquinoline removal, and enantiopure alcohols (+)-S4a and (--)−8a were obtained in 70% and 77% yield, respectively. No erosion of enantiopurity should be expected after this step, given the literature precedents on the synthesis of (--)-paroxetine ([@bib3]) and the absence of acidic protons in the substrate. Therefore, the synthesis was continued exclusively on alcohol derivative (--)−8a. O-Alkylation and Boc-deprotection with HCl finally afforded enantiopure Br-(--)-paroxetine analogue two as the corresponding hydrochloride salt in 12% yield over eight steps from commercial material.](elife-56427-app1-fig16){#app1scheme1}

![Reductive aminoquinoline removal and final steps in the synthesis of Br-(--)-paroxetine 2.\
(**a**) AQ removal on enantiomerically pure *trans-*piperidine (--)-S3a (0.2 mmol, one equiv). (**b**) AQ removal on enantiomerically pure *trans*-piperidine (+)−7a (1.1 mmol, one equiv) and final steps in the synthesis of Br-(--)-paroxetine 2. Full Synthetic Route to Racemic and Enantioenriched I-Piperidine Derivatives (±)-S2b, (±)-S3b, (+)−6b, (+)−7b, (--)-S3b, (--)−8b, (+)-S4b, (--)−9b and I-(--)-paroxetine 3 Similarly to the Br-analogue, C--H arylation with 1,4-diiodobenzene was performed on both racemic ((±)-S1) and enantioenriched ((--)−5) piperidine amide substrates ([Scheme 3](#app1scheme3){ref-type="fig"}). The reaction proceeded well on both substrates affording racemic *cis-* and *trans-*arylated products (±)-S2b and (±)-S3b in 35% and 19% yield, and enantioenriched *cis-* and *trans-*derivatives (+)−6b and (--)-S3b in 35% and 20% yield respectively.](elife-56427-app1-fig17){#app1scheme2}

![Synthetic sequence, including the Pd-catalyzed C(4)--H arylation step, to access racemic and enantioenriched *cis-* and *trans-*piperidine amide derivatives (±)-S2b, (±)-S3b, (+)−6b, (+)−7b and (--)-S3b.\
(**a**) C--H Arylation conditions: (±)-S1 (0.5 mmol, one equiv) Ph-CF~3~ (500 μL, 1 M). (**b**) C--H Arylation conditions: (--)−5 (4.0 mmol, one equiv), Ph-CF~3~ (2.0 mL, 2 M). Reductive aminoquinoline cleavage was again performed to access enantiomeric *trans*-piperidine alcohols (+)-S4b and (--)−8b ([Scheme 4](#app1scheme4){ref-type="fig"}). In both cases, a small degree of LiAlH~4~-mediated dehalogenation was observed, and an inseparable mixture of the desired product and 10--15% of deiodinated material was isolated. However, the contaminant could be effectively removed after O-Alkylation, affording the pure aryl ether derivative (--)−9b in 71% yield. Final HCl-mediated Boc deprotection formed the desired I-(--)-paroxetine three as the corresponding HCl salt in 81% yield (12% yield over eight steps from commercial material).](elife-56427-app1-fig18){#app1scheme3}

![Reductive aminoquinoline removal and final steps in the synthesis of I-(--)-paroxetine 3.\
(**a**) AQ removal on enantiomerically pure *trans-*piperidine (--)-S3b (0.2 mmol, one equiv). (**b**) AQ removal on enantiomerically pure *trans*-piperidine (+)−7b (1.0 mmol, one equiv) and final steps in the synthesis of I-(--)-paroxetine 3.](elife-56427-app1-fig19){#app1scheme4}

Experimental details and characterization data {#s10}
==============================================

Synthesis of Br-analogue of (--)-paroxetine (compounds (±)-S2a, (±)-S3a, (+)−6a, (+)−7a, (--)-S3a, (--)−8a, (+)-S4a, (--)−9a and 2 ∙ HCl).

![*tert-*Butyl *cis-*(±)−4-(4-bromophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((±)-S2a) and *tert-*butyl *trans-*(±)−4*-*(4*-*bromophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl)piperidine*-*1*-*carboxylate ((±)-S3a).](elife-56427-app1-fig2){#app1chem2}

A reaction tube was charged with K~2~CO~3~ (69.1 mg, 0.50 mmol, one equiv), flame-dried, and allowed to cool under argon. *tert*-Butyl (±)−3-(quinoline-8-ylcarbamoyl)piperidine-1-carboxylate ((±)-S1) (178 mg, 0.50 mmol, one equiv), 4-bromoiodobenzene (424 mg, 1.50 mmol, three equiv), Pd(OAc)~2~ (5.60 mg, 25.0 μmol, 5 mol %) and PivOH (51.2 mg, 0.50 mmol, one equiv) were added sequentially. The reaction vessel was sealed with an aluminum cap (with molded butyl/PTFE septa) and purged with argon, then anhydrous PhCF~3~ (500 μL, 1.0 M) was added by syringe. The reaction tube was then placed in a preheated oil bath and stirred at 110°C for 18 hr. The reaction mixture was allowed to cool to rt and EtOAc (10 mL) was added. The resulting mixture was filtered through a pad of Celite, eluting with further EtOAc (2 × 10 mL). The solvent was removed under reduced pressure, and the crude material was purified by flash column chromatography (0% to 5% CH~3~CN/CH~2~Cl~2~). The product containing fractions were combined and the solvent was removed under reduced pressure. Et~2~O (5 mL) and pentane (5 mL) were added and the solvent was removed under reduced pressure to afford the minor product *tert--*butyl *trans-*(±)−4*-*(4*-*bromophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl) piperidine*-*1*-*carboxylate (±)-S3a as a pale yellow solid (34.5 mg, 14%) followed by the major product *tert-*butyl *cis-*(±)−4*-*(4*-*bromophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl)piperidine*-*1*-*carboxylate (±)-S2a as an off-white solid (87.2 mg, 34%).

Major ((±)-S2a) {#s10-1}
---------------

R~f~0.31 (5% CH~3~CN/CH~2~Cl~2~); mp = 81--86°C (from Et~2~O/pentane);

ν~max~ (film)/cm^--1^3343 (NH), 2859, 1684 (C = O), 1521, 1484, 1423, 1364, 1323, 1245, 1163, 1006, 827, 790, 757;

^1^H NMR (500 MHz, (CD~3~)~2~SO, 373 K) δ 9.75 (br s, 1 hr, NH), 8.83 (dd, *J* = 4.2, 1.7 Hz, 1 hr, HC~Ar~), 8.45 (dd, *J* = 7.7, 1.4 Hz, 1 hr, HC~Ar~), 8.31 (dd, *J* = 8.3, 1.7 Hz, 1 hr, HC~Ar~), 7.60--7.53 (m, 2 hr, HC~Ar~), 7.48 (t, *J* = 7.9 Hz, 1 hr, HC~Ar~), 7.40--7.34 (m, 2 hr, HC~Ar~), 7.33--7.26 (m, 2 hr, HC~Ar~), 4.42 (ddd, *J* = 14.8, 3.6, 1.7 Hz, 1 hr, NC*H*HCHCO), 4.25 (ddt, *J* = 13.1, 4.6, 2.3 Hz, 1 hr, NC*H*HCH~2~), 3.36--3.28 (m, 2 hr, NCH*H*CHCO, CHCO), 3.16 (dt, *J* = 12.2, 4.0 Hz, 1 hr, CHAr), 3.02--2.92 (m, 1 hr, NCH*H*CH~2~), 2.68 (qd, *J* = 12.4, 4.7 Hz, 1 hr, NCH~2~C*H*H), 1.72 (dq, *J* = 12.9, 3.2 Hz, 1 hr, NCH~2~CH*H*), 1.25 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (126 MHz, (CD~3~)~2~SO, 373 K) δ 169.8 (C = O amide), 153.4 (C = O carbamate), 147.9 (C~Ar~), 142.0 (C~Ar~ quat), 137.6 (C~Ar~ quat), 135.7 (C~Ar~), 133.9 (C~Ar~ quat), 130.3 (2 × C~Ar~), 129.1 (2 × C~Ar~), 127.2 (C~Ar~ quat), 126.1 (C~Ar~), 121.2 (C~Ar~), 120.8 (C~Ar~), 118.7 (BrC~Ar~ quat), 115.7 (C~Ar~), 77.9 (*C*(CH~3~)~3~), 46.2 (N*C*H~2~CHCO), 45.6 (*C*HCO), 42.9 (N*C*H~2~CH~2~), 41.7 (*C*HAr), 27.4 (C(*C*H~3~)~3~), 25.0 (NCH~2~*C*H~2~);

HRMS (ESI^+^) *m/z* Calculated for C~26~H~29~N~3~O~3~^79^Br \[M+H\] 510.1392; Found 510.1386.

SMILES: O = C(\[C\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(Br)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3

InChI = 1S/C26H28BrN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21-/m0/s1

Minor ((±)-S3a) {#s10-2}
---------------

R~f~0.41 (5% CH~3~CN/CH~2~Cl~2~); mp = 77--83°C (from Et~2~O/pentane);

ν~max~ (film)/cm^--1^3340 (NH), 2926, 1677 (C = O), 1521, 1484, 1424, 1323, 1230, 1156, 1126, 999, 824, 757;

^1^H NMR (500 MHz, (CD~3~)~2~SO, 373 K) δ 9.73 (br s, 1 hr, NH), 8.85 (dd, *J* = 4.2, 1.7 Hz, 1 hr, HC~Ar~), 8.39 (dd, *J* = 7.7, 1.4 Hz, 1 hr, HC~Ar~), 8.31 (dd, *J* = 8.3, 1.7 Hz, 1 hr, HC~Ar~), 7.61--7.54 (m, 2 hr, HC~Ar~), 7.47 (t, *J* = 8.0 Hz, 1 hr, HC~Ar~), 7.39--7.32 (m, 2 hr, HC~Ar~), 7.34--7.28 (m, 2 hr, HC~Ar~), 4.36 (ddd, *J* = 12.9, 3.7, 1.8 Hz, 1 hr, NC*H*HCHCO), 4.13 (ddt, *J* = 13.3, 4.3, 2.2 Hz, 1 hr, NC*H*HCH~2~), 3.18--3.00 (m, 3 hr, NCH*H*CHCO, CHCO, CHAr), 2.99--2.90 (m, 1 hr, NCH*H*CH~2~), 1.81 (dq, *J* = 12.9, 2.8 Hz, 1 hr, NCH~2~C*H*H), 1.66 (qd, *J* = 12.8, 4.6 Hz, 1 hr, NCH~2~CH*H*), 1.49 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (126 MHz, (CD~3~)~2~SO, 373 K) δ 169.8 (C = O amide), 153.4 (C = O carbamate), 148.0 (C~Ar~), 142.4 (C~Ar~ quat), 137.7 (C~Ar~ quat), 135.7 (C~Ar~), 133.5 (C~Ar~ quat), 130.6 (2 × C~Ar~), 129.1 (2 × C~Ar~), 127.2 (C~Ar~ quat), 126.1 (C~Ar~), 121.4 (C~Ar~), 121.3 (C~Ar~), 118.9 (BrC~Ar~ quat), 116.3 (C~Ar~), 78.6 (*C*(CH~3~)~3~), 49.2 (*C*HCO), 46.2 (N*C*H~2~CHCO), 43.9 (*C*HAr), 43.3 (N*C*H~2~CH~2~), 32.0 (NCH~2~*C*H~2~), 27.7 (C(*C*H~3~)~3~);

HRMS (ESI^+^) *m/z* Calculated for C~26~H~29~N~3~O~3~^79^Br \[M+H\] 510.1392; Found 510.1382.

SMILES: O = C(\[C@\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(Br)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3

InChI = 1S/C26H28BrN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21+/m0/s1

![*tert-*Butyl (+)-(*3R,4R*)−4*-*(4*-*bromophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl)piperidine*-*1*-*carboxylate ((+)−6a) and *tert*-butyl (--)-(*3R,4S*)−4-(4-bromophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((--)-S3a).](elife-56427-app1-fig3){#app1chem3}

A large microwave vial (10--20 mL recommended volume) was charged with K~2~CO~3~ (553 mg, 4.0 mmol, one equiv), flame-dried, and allowed to cool under argon. *tert*-Butyl (*R*)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate (*--*)−5 (1.42 g, 4.0 mmol, one equiv), 4-bromoiodobenzene (3.40 g, 12.0 mmol, three equiv), Pd(OAc)~2~ (45.1 mg, 0.2 mmol, 5 mol %) and PivOH (409 mg, 4.0 mmol, one equiv) were added sequentially. The reaction vessel was sealed with an aluminum cap (with molded butyl/PTFE septa) and purged with argon, then anhydrous PhCF~3~ (2.0 mL, 2.00 M) was added by syringe. The reaction tube was then placed in a preheated oil bath and stirred at 110°C for 18 hr. The reaction mixture was then allowed to cool to rt and EtOAc (20 mL) was added. The resulting mixture was filtered through a pad of Celite, eluting with further EtOAc (2 × 50 mL). The solvent was removed under reduced pressure. The reaction mixture was purified by two consecutive chromatographic separations: one (0% to 5% CH~3~CN/CH~2~Cl~2~) to isolate the minor *trans-*product *tert*-butyl (--)-(*3R,4S*)−4-(4-bromophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate (--)-S3a followed by a second (10% to 15% acetone/pentane) to isolate the major *cis-*product *tert*-butyl (+)-(*3R,4R*)−4-(4-bromophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate (+)−6a. The product containing fractions were combined and the solvent was removed under reduced pressure. Et~2~O (20 mL) and pentane (20 mL) were added and the solvent was removed under reduced pressure to afford the minor *trans-*product (--)-S3a as a pale yellow solid (371 mg, 18%, 98.0% *ee*) and the major *cis-*product (+)−6a as a white solid (730 mg, 36%, 98.2% *ee*).

Major ((+)−6a) {#s10-3}
--------------

$\left\lbrack \alpha \right\rbrack_{D}^{23}$ + 15.4 (*c* 1.3, CHCl~3~).

Characterization data identical to that reported for racemic *cis-*piperidine (±)-S2a (see S17).

HPLC Conditions: Chiralpak IA 3-column, 85:15 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 210.4 nm. Retention times: 11.9 min (3*S,*4*S* enantiomer), 17.3 min (3*R,*4*R* enantiomer).

SMILES: O = C(\[C\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(Br)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3

InChI = 1S/C26H28BrN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21-/m0/s1

Minor ((--)-S3a) {#s10-4}
----------------

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 35.4 (*c* 1.3, CHCl~3~).

Characterization data identical to that reported for racemic *trans-*piperidine (±)-S3a (see S17).

HPLC Conditions: Chiralpak IA 3-column, 85:15 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 254.1 nm. Retention times: 9.1 min (3*R,*4*S* enantiomer), 12.2 min (3*S,*4*R* enantiomer).

SMILES: O = C(\[C\@H\]1CN(C(OC(C)(C)C)=O)CC\[C@\@H\]1C2 = CC = C(Br)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28BrN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21+/m1/s1.

![*tert*-Butyl (+)-(*3S,4R*)−4-(4-bromophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((+)−7a).](elife-56427-app1-fig4){#app1chem4}

A flame-dried reaction tube was charged with *cis-*3,4-disubstituted piperidine (+)−6a (662 mg, 1.30 mmol, one equiv) and 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU, 600 μL, 3.90 mmol, three equiv). The reaction vessel was sealed with an aluminum cap (with molded butyl/PTFE septa) and purged with argon, then anhydrous toluene (1.30 mL, 1.0 M) was added by syringe. The reaction tube was then placed in a preheated oil bath and stirred at 110°C for 24 hr. The reaction mixture was then allowed to cool to rt and CH~2~Cl~2~ (5 mL) and sat. aq. NH~4~Cl (5 mL) were added. The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. The reaction mixture was purified by flash column chromatography (15% acetone/pentane). The product containing fractions were combined and the solvent was removed under reduced pressure. Et~2~O (10 mL) and pentane (10 mL) were added and the solvent was removed under reduced pressure to afford amide *tert*-butyl (+)-(*3S,4R*)−4-(4-bromophenyl)−3-(quinolin-8-ylcarbamoyl) piperidine-1-carboxylate (+)−7a as a white solid (621 mg, 94%, 98.4% *ee*).

$\left\lbrack \alpha \right\rbrack_{D}^{23}$ + 52.0 (*c* 1.0, CHCl~3~).

Characterization data identical to that reported for racemic *trans-*piperidine (±)-S3a (see S17).

HPLC Conditions: Chiralpak IA 3-column, 85:15 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 254.1 nm. Retention times: 9.1 min (3*R,*4*S* enantiomer), 12.2 min (3*S,*4*R* enantiomer).

SMILES: O = C(\[C@\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(Br)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28BrN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21+/m0/s1.

![*tert*-Butyl (+)-(*3R,4S*)−4-(4-bromophenyl)−3-(hydroxymethyl)piperidine-1-carboxylate ((+)-S4a).](elife-56427-app1-fig5){#app1chem5}

A flame-dried reaction tube was charged with amide (--)-S3a (102 mg, 0.20 mmol, one equiv), followed by di-*tert*-butyl dicarbonate (Boc~2~O, 175 mg, 0.80 mmol, four equiv) and 4-(dimethylamino)pyridine (DMAP, 4.9 mg, 0.04 mmol, 20 mol %). The reaction vessel was sealed with an aluminum cap (with molded butyl septa) and purged with argon, then anhydrous MeCN (400 μL, 0.5 M) was added by syringe. The mixture was then stirred at 35°C for 22 hr. The reaction mixture was then allowed to cool to rt and sat. aq. NH~4~Cl (1 mL) and CH~2~Cl~2~ (1 mL) were added. The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 5 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure to afford the crude *N*-Boc protected piperidine derivative.

This crude was solubilized in anhydrous THF (800 μL, 0.2 M) and the resulting solution was added dropwise to a suspension of LiAlH~4~ (15.2 mg, 0.40 mmol, two equiv) in anhydrous THF (200 μL, 2.0 M) at 0°C under argon atmosphere. The mixture was then stirred at 20°C for 30 min. The reaction mixture was then quenched by slow addition of sat. aq. NH~4~Cl (2 mL) at 0°C and stirred at rt for 30 min. The resulting suspension was filtered through a pad of Celite, eluting with EtOAc (3 × 5 mL). The phases were separated, and the aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. Purification by flash column chromatography (10% to 20% acetone/hexane) afforded primary alcohol (+)-S4a as a yellow solid (52.0 mg, 70% over two steps, 98.1% *ee*).

$\left\lbrack \alpha \right\rbrack_{D}^{23}$ + 5.0 (*c* 0.8, CHCl~3~).

R~f~0.21 (20% acetone/hexane); mp = 49--54°C;

ν~max~ (film)/cm^--1^3407 (OH), 2922, 1662 (C = O), 1476, 1424, 1230, 1159, 1129, 1059, 1006, 816, 769;

^1^H NMR (400 MHz, CDCl~3~, 298 K) δ 7.47--7.40 (m, 2 hr, HC~Ar~), 7.11--7.05 (m, 2 hr, HC~Ar~), 4.36 (br d, *J* = 13.2 Hz, 1 hr, NC*H*HCHCH~2~OH), 4.20 (br s, 1 hr, NC*H*HCH~2~), 3.43 (dd, *J* = 11.0, 3.1 Hz, 1 hr, C*H*HOH), 3.26 (dd, *J* = 11.0, 6.4 Hz, 1 hr, CH*H*OH), 2.87--2.62 (m, 2 hr, NCH*H*CHCH~2~OH, NCH*H*CH~2~), 2.59--2.47 (m, 1 hr, CHAr), 1.88--1.59 (m, 4 hr, C*H*CH~2~OH, NCH~2~C*H~2~*, OH), 1.49 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (101 MHz, CDCl~3~, 298 K, observed as a mixture of rotamers) δ 154.8 (C = O), 142.8 (C~Ar~ quat), 131.8 (2 × C~Ar~), 129.1 (2 × C~Ar~), 120.3 (BrC~Ar~ quat), 79.7 (*C*(CH~3~)~3~), 62.9 (*C*H~2~OH), 46.5 (br m, N*C*H~2~CHCH~2~OH), 44.2 and 43.6 (N*C*H~2~CH~2~, *C*HAr, *C*HCH~2~OH), 33.8 (NCH~2~*C*H~2~), 28.5 (C(*C*H~3~)~3~);

HRMS (ESI^+^) *m/z* Calculated for C~19~H~27~N~2~O~3~Na^79^Br \[M+CH~3~CN+Na Adduct\] 433.1103; Found 433.1110.

HPLC Conditions: Chiralpak ID 3-column, 90:10 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 210.4 nm. Retention times: 8.0 min (3*R,*4*S* enantiomer), 8.6 min (3*S,*4*R* enantiomer).

SMILES: BrC1 = CC = C(\[C@\@H\]2\[C@\@H\](CO)CN(C(OC(C)(C)C)=O)CC2)C = C1.

InChI = 1S/C17H24BrNO3/c1-17(2,3)22-16(21)19-9-8-15(13(10-19)11--20)12-4-6-14(18)7-5-12/h4-7,13,15,20H,8--11 H2,1--3 H3/t13-,15-/m1/s1.

![*tert*-Butyl (--)-(3*S,*4*R*)−4-(4-bromophenyl)−3-(hydroxymethyl)piperidine-1-carboxylate ((--)−8a).](elife-56427-app1-fig6){#app1chem6}

A flame-dried round-bottom flask was charged with amide (+)−7a (565 mg, 1.11 mmol, one equiv), followed by di-*tert*-butyl dicarbonate (Boc~2~O, 969 mg, 4.44 mmol, four equiv) and 4-(dimethylamino)pyridine (DMAP, 26.9 mg, 0.22 mmol, 20 mol %). The reaction vessel was sealed with an aluminum cap (with molded butyl septa) and purged with argon, then anhydrous MeCN (3.7 mL) and anhydrous CH~2~Cl~2~ (0.5 mL) were added by syringe. The mixture (0.3 M) was then stirred at 35°C for 22 hr. The reaction mixture was then allowed to cool to rt and sat. aq. NH~4~Cl (5 mL) and CH~2~Cl~2~ (5 mL) were added. The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure to afford the crude *N*-Boc protected piperidine derivative.

This crude was solubilized in anhydrous THF (3.5 mL, 0.3 M) and the resulting solution was added dropwise to a suspension of LiAlH~4~ (84.2 mg, 2.22 mmol, two equiv) in anhydrous THF (2.0 mL, 1.0 M) at 0°C under argon atmosphere. The mixture was then stirred at 20°C for 30 min. The reaction mixture was then quenched by slow addition of sat. aq. NH~4~Cl (5 mL) at 0°C and stirred at rt for 30 min. The resulting suspension was filtered through a pad of Celite, eluting with EtOAc (3 × 10 mL). The phases were separated, and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. Purification by flash column chromatography (10% to 20% acetone/hexane) afforded primary alcohol (--)−8a as a white solid (316 mg, 77% over two steps, 98.1% *ee*).

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 8.0 (*c* 1.0, CHCl~3~).

Characterization data identical to that reported for enantiomeric alcohol (+)-S4a (see S20).

HPLC Conditions: Chiralpak ID 3-column, 90:10 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 210.4 nm. Retention times: 8.0 min (3*R,*4*S* enantiomer), 8.6 min (3*S,*4*R* enantiomer).

SMILES: BrC1 = CC = C(\[C\@H\]2\[C\@H\](CO)CN(C(OC(C)(C)C)=O)CC2)C = C1.

InChI = 1S/C17H24BrNO3/c1-17(2,3)22-16(21)19-9-8-15(13(10-19)11--20)12-4-6-14(18)7-5-12/h4-7,13,15,20H,8--11 H2,1--3 H3/t13-,15-/m0/s1.

![*tert*-Butyl (3*S*,4*R*)−3-((benzo\[*d*\]\[1,3\]dioxol-5-yloxy)methyl)−4-(4-bromophenyl)piperidine-1-carboxylate ((--)−9a).](elife-56427-app1-fig7){#app1chem7}

Alcohol (--)−8a (280 mg, 0.76 mmol, one equiv) and triethylamine (147 μL, 1.10 mmol, 1.4 equiv) were added to a flame-dried round-bottom flask, dissolved in anhydrous CH~2~Cl~2~ (4.0 mL, 0.2 M) and cooled down to 0°C. Methanesulfonyl chloride (75 μL, 0.97 mmol, 1.3 equiv) was then added by Gilson pipette. After stirring 5 min at 0°C, the reaction mixture was stirred at 25°C for 2 hr, then diluted with CH~2~Cl~2~ (5 mL) and sat. aq. NaHCO~3~ (5 mL). The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure to afford the crude mesylated alcohol derivative.

NaH (60% dispersion in mineral oil, 51.8 mg, 1.30 mmol, 1.7 equiv) was added to a solution of sesamol (168 mg, 1.20 mmol, 1.6 equiv) in anhydrous THF (4.0 mL, 0.3 M) at 0°C. The mixture was then stirred at 25°C for 1 hr. A solution of the crude mesylated alcohol in anhydrous THF (5.0 mL, 0.1 M) was then added dropwise to this suspension. The resulting mixture was stirred at 70°C for 18 hr. The reaction mixture was then quenched by addition of H~2~O (5 mL) and diluted with EtOAc (5 mL). The phases were separated, and the aqueous layer was extracted with EtOAc (4 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. Purification by flash column chromatography (5% acetone/pentane) afforded piperidine (--)−9a as a white solid (225 mg, 60% over two steps).

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 36.0 (*c* 1.0, CHCl~3~).

R~f~0.20 (5% acetone/pentane); mp = 53--58°C;

ν~max~ (film)/cm^--1^ 2915, 1685 (C = O), 1483, 1424, 1230, 1163, 1129, 1036, 928, 816, 769;

^1^H NMR (400 MHz, CDCl~3~, 298 K) δ 7.45--7.38 (m, 2 hr, HC~Ar~), 7.10--7.03 (m, 2 hr, HC~Ar~), 6.64 (d, *J* = 8.5 Hz, 1 hr, HC~Ar~), 6.36 (d, *J* = 2.5 Hz, 1 hr, HC~Ar~), 6.14 (dd, *J* = 8.5, 2.5 Hz, 1 hr, HC~Ar~), 5.89 (s, 2 hr, OCH~2~O), 4.44 (br s, 1 hr, NC*H*HCHCH~2~OAr), 4.25 (br s, 1 hr, NC*H*HCH~2~), 3.61 (dd, *J* = 9.4, 2.8 Hz, 1 hr, C*H*HOAr), 3.45 (dd, *J* = 9.4, 6.4 Hz, 1 hr, CH*H*OAr), 2.92--2.73 (br m, 2 hr, NCH*H*CHCH~2~OAr, NCH*H*CH~2~), 2.67 (td, *J* = 11.7, 3.9 Hz, 1 hr, CHAr), 2.08--1.97 (br m, 1 hr, C*H*CH~2~OAr), 1.85--1.77 (br m, 1 hr, NCH~2~C*H*H), 1.72 (td, *J* = 12.6, 4.3 Hz, 1 hr, NCH~2~CH*H*), 1.50 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (101 MHz, CDCl~3~, 298 K) δ 154.7 (C = O), 154.2 (OC~Ar~ quat), 148.1 (OC~Ar~ quat), 142.4 (C~Ar~ quat), 141.7 (OC~Ar~ quat), 131.8 (2 × C~Ar~), 129.1 (2 × C~Ar~), 120.4 (BrC~Ar~ quat), 107.8 (C~Ar~), 105.5 (C~Ar~), 101.1 (OCH~2~O), 98.0 (C~Ar~), 79.7 (*C*(CH~3~)~3~), 68.7 (*C*H~2~OAr), 47.3 (br m, N*C*H~2~CHCH~2~OAr), 44.2 (N*C*H~2~CH~2~, *C*HAr), 41.7 (*C*HCH~2~OAr), 33.7 (NCH~2~*C*H~2~), 28.4 (C(*C*H~3~)~3~);

HRMS (ESI^+^) *m/z* Calculated for C~24~H~29~NO~5~^79^Br \[M+H\] 490.1229; Found 490.1240.

SMILES: BrC1 = CC = C(\[C\@H\]2\[C\@H\](COC3 = CC(OCO4)=C4C = C3)CN(C(OC(C)(C)C)=O)CC2)C = C1.

InChI = 1S/C24H28BrNO5/c1-24(2,3)31-23(27)26-11-10-20(16-4-6-18(25)7-5-16)17(13-26)14-28-19-8-9-21-22(12-19)30-15-29-21/h4-9,12,17,20H,10--11,13-15H2,1--3 H3/t17-,20-/m0/s1.

![(3*S*,4*R*)−3-((Benzo\[d\]\[1,3\]dioxol-5-yloxy)methyl)−4-(4-bromophenyl)piperidine-1-ium chloride (2 ∙ HCl).](elife-56427-app1-fig8){#app1chem8}

4 N HCl in 1,4-dioxane (500 μL, 2.00 mmol, 10 equiv) was added to a solution of *N-*Boc protected piperidine (--)−9a (98.1 mg, 0.20 mmol, one equiv) in 1,4-dioxane (500 μL, 0.4 M) at 0°C under air. The solution was stirred at 25°C for 18 hr, then an ice-cold 1:1 mixture of Et~2~O/pentane (1 mL) was added and formation of a solid precipitate was observed. This was filtered and washed with further ice-cold Et~2~O/pentane mixture (2 × 5 mL). The solid precipitate was dried under reduced pressure to afford (3*S*,4*R*)−3-((benzo\[d\]\[1,3\]dioxol-5-yloxy)methyl)−4-(4-bromophenyl) piperidine-1-ium chloride 2 ∙ HCl as an off-white solid (73.5 mg, 86%).

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 82.0 (*c* 1.0, MeOH); mp = 206--209 °C;

ν~max~ (film)/cm^--1^3317 (NH), 2926, 2687, 1484, 1182, 1103, 1033, 932, 846, 813, 787;

^1^H NMR (400 MHz, CD~3~OD, 298 K) δ 7.50--7.44 (m, 2 hr, HC~Ar~), 7.24--7.18 (m, 2 hr, HC~Ar~), 6.63 (d, *J* = 8.4 Hz, 1 hr, HC~Ar~), 6.39 (d, *J* = 2.5 Hz, 1 hr, HC~Ar~), 6.18 (dd, *J* = 8.5, 2.5 Hz, 1 hr, HC~Ar~), 5.87--5.84 (m, 2 hr, OCH~2~O), 3.71--3.62 (m, 2 hr, C*H*HOAr, NC*H*HCHCH~2~OAr), 3.59--3.49 (m, 2 hr, CH*H*OAr, NC*H*HCH~2~), 2.21--2.11 (m, 2 hr, NCH*H*CHCH~2~OAr, NCH*H*CH~2~), 3.03--2.91 (m, 1 hr, CHAr), 2.49--2.37 (m, 1 hr, C*H*CH~2~OAr), 2.10--2.01 (m, 2 hr, NCH~2~C*H*~2~);

^13^C NMR (101 MHz, CD~3~OD, 298 K) δ 155.3 (OC~Ar~ quat), 149.7 (OC~Ar~ quat), 143.5 (C~Ar~ quat), 142.4 (OC~Ar~ quat), 133.0 (2 × C~Ar~), 130.5 (2 × C~Ar~), 122.0 (BrC~Ar~ quat), 108.8 (C~Ar~), 106.7 (C~Ar~), 102.5 (OCH~2~O), 98.9 (C~Ar~), 69.0 (*C*H~2~OAr), 47.7 (N*C*H~2~CHCH~2~OAr), 45.5 (N*C*H~2~CH~2~), 42.9 (*C*HAr), 40.6 (*C*HCH~2~OAr), 31.4 (NCH~2~*C*H~2~);

HRMS (ESI^+^) *m/z* Calculated for C~19~H~21~NO~3~^79^Br \[M--Cl\] 390.0705; Found 390.0698.

SMILES: BrC1 = CC = C(\[C\@H\]2\[C\@H\](COC3 = CC(OCO4)=C4C = C3)CNCC2)C = C1 .Cl.

InChI = 1S/C19H20BrNO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7--8,10-12H2;1H/t14-,17-;/m0./s1.

Synthesis of I-analogue of (--)-paroxetine (compounds (±)-S2b, (±)-S3b, (+)−6b, (+)−7b, (--)-S3b, (--)−8b, (+)-S4b, (--)−9b and 3 ∙ HCl).

![*tert-*Butyl *cis-*(±)−4-(4-iodophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((±)-S2b) and *tert-*butyl *trans-*(±)−4*-*(4*-*iodophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl)piperidine*-*1*-*carboxylate ((±)-S3b).](elife-56427-app1-fig9){#app1chem9}

A reaction tube was charged with K~2~CO~3~ (69.1 mg, 0.50 mmol, one equiv), flame-dried, and allowed to cool under argon. *tert*-Butyl (±)−3-(quinoline-8-ylcarbamoyl)piperidine-1-carboxylate ((±)-S1) (178 mg, 0.50 mmol, one equiv), 1,4-diiodobenzene (660 mg, 2.00 mmol, four equiv), Pd(OAc)~2~ (5.60 mg, 25.0 μmol, 5 mol %) and PivOH (51.2 mg, 0.50 mmol, one equiv) were added sequentially. The reaction vessel was sealed with an aluminum cap (with molded butyl/PTFE septa) and purged with argon, then anhydrous PhCF~3~ (500 μL, 1.0 M) was added by syringe. The reaction tube was then placed in a preheated oil bath and stirred at 110°C for 18 hr. The reaction mixture was allowed to cool to rt and EtOAc (10 mL) was added. The resulting mixture was filtered through a pad of Celite, eluting with further EtOAc (2 × 10 mL). The solvent was removed under reduced pressure, and the crude material was purified by flash column chromatography (0% to 5% CH~3~CN/CH~2~Cl~2~). The product containing fractions were combined and the solvent was removed under reduced pressure. Et~2~O (5 mL) and pentane (5 mL) were added and the solvent was removed under reduced pressure to afford the minor product *tert--*butyl *trans-*(±)−4*-*(4*-*iodophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl) piperidine*-*1*-*carboxylate (±)-S3b as a pale yellow solid (52.2 mg, 19%) followed by the major product *tert-*butyl *cis-*(±)−4*-*(4*-*iodophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl)piperidine*-*1*-*carboxylate (±)-S2b as a pale yellow solid (97.9 mg, 35%).

Major ((±)-S2b) {#s10-5}
---------------

R~f~0.30 (5% CH~3~CN/CH~2~Cl~2~); mp = 91--95°C (from Et~2~O/pentane);

ν~max~ (film)/cm^--1^3343 (NH), 2926, 1685 (C = O), 1521, 1483, 1424, 1364, 1323, 1245, 1159, 1118, 1003, 824, 790, 757;

^1^H NMR (500 MHz, (CD~3~)~2~SO, 373 K) δ 9.75 (br s, 1 hr, NH), 8.83 (dd, *J* = 4.2, 1.7 Hz, 1 hr, HC~Ar~), 8.45 (dd, *J* = 7.6, 1.4 Hz, 1 hr, HC~Ar~), 8.31 (dd, *J* = 8.3, 1.7 Hz, 1 hr, HC~Ar~), 7.60--7.53 (m, 4 hr, HC~Ar~), 7.48 (t, *J* = 8.0 Hz, 1 hr, HC~Ar~), 7.19--7.12 (m, 2 hr, HC~Ar~), 4.42 (ddd, *J* = 14.9, 3.7, 1.8 Hz, 1 hr, NC*H*HCHCO), 4.25 (ddt, *J* = 13.2, 4.7, 2.4 Hz, 1 hr, NC*H*HCH~2~), 3.35--3.28 (m, 2 hr, NCH*H*CHCO, CHCO), 3.14 (dt, *J* = 12.4, 4.2 Hz, 1 hr, CHAr), 3.01--2.92 (m, 1 hr, NCH*H*CH~2~), 2.67 (qd, *J* = 12.4, 4.6 Hz, 1 hr, NCH~2~C*H*H), 1.71 (dq, *J* = 13.0, 3.4 Hz, 1 hr, NCH~2~CH*H*), 1.25 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (126 MHz, (CD~3~)~2~SO, 373 K) δ 169.8 (C = O amide), 153.4 (C = O carbamate), 147.9 (C~Ar~), 142.5 (C~Ar~ quat), 137.6 (C~Ar~ quat), 136.3 (2 × C~Ar~), 135.7 (C~Ar~), 133.9 (C~Ar~ quat), 129.3 (2 × C~Ar~), 127.2 (C~Ar~ quat), 126.1 (C~Ar~), 121.2 (C~Ar~), 120.8 (C~Ar~), 115.7 (C~Ar~), 90.9 (IC~Ar~ quat), 77.9 (*C*(CH~3~)~3~), 46.2 (N*C*H~2~CHCO), 45.6 (*C*HCO), 42.9 (N*C*H~2~CH~2~), 41.8 (*C*HAr), 27.4 (C(*C*H~3~)~3~), 25.0 (NCH~2~*C*H~2~);

HRMS (ESI^+^) *m/z* Calculated for C~26~H~29~N~3~O~3~^127^I \[M+H\] 558.1254; Found 558.1260.

SMILES: O = C(\[C\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(I)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28IN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21-/m0/s1.

Minor ((±)-S3b) {#s10-6}
---------------

R~f~0.41 (5% CH~3~CN/CH~2~Cl~2~); mp = 93--96°C (from Et~2~O/pentane); ν~max~ (film)/cm^--1^3336 (NH), 2922, 1677 (C = O), 1521, 1483, 1424, 1323, 1230, 1156, 1062, 1003, 824, 757;

^1^H NMR (500 MHz, (CD~3~)~2~SO, 373 K) δ 9.73 (br s, 1 hr, NH), 8.85 (dd, *J* = 4.2, 1.7 Hz, 1 hr, HC~Ar~), 8.39 (dd, *J* = 7.7, 1.3 Hz, 1 hr, HC~Ar~), 8.31 (dd, *J* = 8.3, 1.7 Hz, 1 hr, HC~Ar~), 7.62--7.55 (m, 2 hr, HC~Ar~), 7.55--7.51 (m, 2 hr, HC~Ar~), 7.47 (t, *J* = 8.0 Hz, 1 hr, HC~Ar~), 7.19--7.14 (m, 2 hr, HC~Ar~), 4.35 (ddd, *J* = 12.8, 3.8, 1.8 Hz, 1 hr, NC*H*HCHCO), 4.12 (ddt, *J* = 13.3, 4.4, 2.1 Hz, 1 hr, NC*H*HCH~2~), 3.17--2.99 (m, 3 hr, NCH*H*CHCO, CHCO, CHAr), 2.98--2.90 (m, 1 hr, NCH*H*CH~2~), 1.80 (dq, *J* = 13.3, 3.0 Hz, 1 hr, NCH~2~C*H*H), 1.65 (qd, *J* = 12.7, 4.6 Hz, 1 hr, NCH~2~CH*H*), 1.48 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (126 MHz, (CD~3~)~2~SO, 373 K) δ 169.8 (C = O amide), 153.4 (C = O carbamate), 148.1 (C~Ar~), 142.8 (C~Ar~ quat), 137.7 (C~Ar~ quat), 136.6 (2 × C~Ar~), 135.7 (C~Ar~), 133.5 (C~Ar~ quat), 129.3 (2 × C~Ar~), 127.2 (C~Ar~ quat), 126.1 (C~Ar~), 121.4 (C~Ar~), 121.3 (C~Ar~), 116.3 (C~Ar~), 91.1 (IC~Ar~ quat), 78.6 (*C*(CH~3~)~3~), 49.1 (*C*HCO), 46.2 (N*C*H~2~CHCO), 44.0 (*C*HAr), 43.3 (N*C*H~2~CH~2~), 32.0 (NCH~2~*C*H~2~), 27.7 (C(*C*H~3~)~3~);

HRMS (ESI^+^) *m/z* Calculated for C~26~H~29~N~3~O~3~^127^I \[M+H\] 558.1254; Found 558.1247.

SMILES: O = C(\[C@\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(I)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28IN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21+/m0/s1.

![*tert-*Butyl (+)-(*3R,4R*)−4*-*(4*-*iodophenyl)−3*-*(quinolin*-*8*-*ylcarbamoyl)piperidine*-*1*-*carboxylate ((+)−6b) and *tert*-butyl (--)-(*3R,4S*)−4-(4-iodophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((--)-S3b).](elife-56427-app1-fig10){#app1chem10}

A large microwave vial (10--20 mL recommended volume) was charged with K~2~CO~3~ (553 mg, 4.0 mmol, one equiv), flame-dried, and allowed to cool under argon. *tert*-Butyl (*R*)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate (*--*)−5 (1.42 g, 4.0 mmol one equiv), 1,4-diiodobenzene (5.28 g, 16.0 mmol, four equiv), Pd(OAc)~2~ (45.1 mg, 0.2 mmol, 5 mol %) and PivOH (409 mg, 4.0 mmol, one equiv) were added sequentially. The reaction vessel was sealed with an aluminum cap (with molded butyl/PTFE septa) and purged with argon, then anhydrous PhCF~3~ (2.0 mL, 2.00 M) was added by syringe. The reaction tube was then placed in a preheated oil bath and stirred at 110°C for 18 hr. The reaction mixture was then allowed to cool to rt and EtOAc (20 mL) was added. The resulting mixture was filtered through a pad of Celite, eluting with further EtOAc (2 × 50 mL). The solvent was removed under reduced pressure. The reaction mixture was purified by two consecutive chromatographic separations: one (0% to 5% CH~3~CN/CH~2~Cl~2~) to isolate the minor *trans-*product *tert*-butyl (--)-(*3R,4S*)−4-(4-iodophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate (--)-S3b followed by a second (10% to 15% acetone/pentane) to isolate the major *cis-*product *tert*-butyl (+)-(*3R,4R*)−4-(4-iodophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate (+)−6b. The product containing fractions were combined and the solvent was removed under reduced pressure. Et~2~O (20 mL) and pentane (20 mL) were added and the solvent was removed under reduced pressure to afford the minor *trans-*product (--)-S3b as a pale orange solid (441 mg, 20%, 98.1% *ee*) and the major *cis-*product (+)−6b (775 mg, 35%, 98.2% *ee*).

Major ((+)−6b) {#s10-7}
--------------

$\left\lbrack \alpha \right\rbrack_{D}^{23}$ + 9.1 (*c* 1.1, CHCl~3~).

Characterization data identical to that reported for racemic *cis-*piperidine (±)-S2b (see S24).

HPLC Conditions: Chiralpak IA 3-column, 85:15 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 210.4 nm. Retention times: 12.2 min (3*S,*4*S* enantiomer), 17.7 min (3*R,*4*R* enantiomer).

SMILES: O = C(\[C\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(I)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28IN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21-/m0/s1.

Minor ((--)-S3b) {#s10-8}
----------------

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 45.5 (*c* 1.1, CHCl~3~).

Characterization data identical to that reported for racemic *trans-*piperidine (±)-S3b (see S24).

HPLC Conditions: Chiralpak IA 3-column, 85:15 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 254.1 nm. Retention times: 9.4 min (3*R,*4*S* enantiomer), 13.3 min (3*S,*4*R* enantiomer).

SMILES: O = C(\[C\@H\]1CN(C(OC(C)(C)C)=O)CC\[C@\@H\]1C2 = CC = C(I)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28IN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21+/m1/s1.

![*tert*-Butyl (+)-(*3S,4R*)−4-(4-iodophenyl)−3-(quinolin-8-ylcarbamoyl)piperidine-1-carboxylate ((+)−7b).](elife-56427-app1-fig11){#app1chem11}

A flame-dried reaction tube was charged with *cis-*3,4-disubstituted piperidine (+)−6b (687 mg, 1.23 mmol, one equiv) and 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU, 550 μL, 3.70 mmol, three equiv). The reaction vessel was sealed with an aluminum cap (with molded butyl/PTFE septa) and purged with argon, then anhydrous toluene (1.20 mL, 1.0 M) was added by syringe. The reaction tube was then placed in a preheated oil bath and stirred at 110°C for 24 hr. The reaction mixture was then allowed to cool to rt and CH~2~Cl~2~ (5 mL) and sat. aq. NH~4~Cl (5 mL) were added. The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. The reaction mixture was purified by flash column chromatography (10% acetone/pentane). The product containing fractions were combined and the solvent was removed under reduced pressure. Et~2~O (10 mL) and pentane (10 mL) were added and the solvent was removed under reduced pressure to afford amide *tert*-butyl (+)-(*3S,4R*)−4-(4-iodophenyl)−3-(quinolin-8-ylcarbamoyl) piperidine-1-carboxylate (+)−7b as a white solid (626 mg, 91%, 98.0% *ee*).

$\left\lbrack \alpha \right\rbrack_{D}^{23}$ + 48.0 (*c* 1.0, CHCl~3~).

Characterization data identical to that reported for racemic *trans-*piperidine (±)-S3b (see S24).

HPLC Conditions: Chiralpak IA 3-column, 85:15 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 254.1 nm. Retention times: 9.4 min (3*R,*4*S* enantiomer), 13.3 min (3*S,*4*R* enantiomer).

SMILES: O = C(\[C@\@H\]1CN(C(OC(C)(C)C)=O)CC\[C\@H\]1C2 = CC = C(I)C = C2)NC3 = C(N = CC = C4)C4 = CC = C3.

InChI = 1S/C26H28IN3O3/c1-26(2,3)33-25(32)30-15-13-20(17-9-11-19(27)12-10-17)21(16-30)24(31)29-22-8-4-6-18-7-5-14-28-23(18)22/h4-12,14,20--21H,13,15--16 H2,1--3 H3,(H,29,31)/t20-,21+/m0/s1.

![*tert*-Butyl (+)-(*3R,4S*)−4-(4-iodophenyl)−3-(hydroxymethyl)piperidine-1-carboxylate ((+)-S4b) .](elife-56427-app1-fig12){#app1chem12}

A flame-dried reaction tube was charged with amide (--)-S3b (111 mg, 0.20 mmol, one equiv), followed by di-*tert*-butyl dicarbonate (Boc~2~O, 175 mg, 0.80 mmol, four equiv) and 4-(dimethylamino)pyridine (DMAP, 4.9 mg, 0.04 mmol, 20 mol %). The reaction vessel was sealed with an aluminum cap (with molded butyl septa) and purged with argon, then anhydrous MeCN (400 μL, 0.5 M) was added by syringe. The mixture was then stirred at 40°C for 22 hr. The reaction mixture was then allowed to cool to rt and sat. aq. NH~4~Cl (1 mL) and CH~2~Cl~2~ (1 mL) were added. The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 5 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure to afford the crude *N*-Boc protected piperidine derivative.

This crude was solubilized in anhydrous THF (800 μL, 0.2 M) and the resulting solution was added dropwise to a suspension of LiAlH~4~ (15.2 mg, 0.40 mmol, two equiv) in anhydrous THF (200 μL, 2.0 M) at 0°C under argon atmosphere. The mixture was then stirred at 20°C for 30 min. The reaction mixture was then quenched by slow addition of sat. aq. NH~4~Cl (2 mL) at 0°C and stirred at rt for 30 min. The resulting suspension was filtered through a pad of Celite, eluting with EtOAc (3 × 5 mL). The phases were separated, and the aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. Purification by flash column chromatography (10% to 15% acetone/pentane) afforded primary alcohol (+)-S4b as a white solid (52.3 mg, 63% over two steps, 98.1% *ee*, containing approx. 10% deiodinated derivative).

$\left\lbrack \alpha \right\rbrack_{D}^{23}$ + 2.0 (*c* 1.0, CHCl~3~).

R~f~0.24 (15% acetone/pentane); mp = 53--59°C;

ν~max~ (film)/cm^--1^3422 (OH), 2922, 1662 (C = O), 1479, 1424, 1364, 1234, 1163, 1129, 1059, 1006, 816, 764; ^1^H NMR (400 MHz, CDCl~3~, 298 K) δ 7.66--7.61 (m, 2 hr, HC~Ar~), 6.99--6.93 (m, 2 hr, HC~Ar~), 4.36 (br d, *J* = 13.2 Hz, 1 hr, NC*H*HCHCH~2~OH), 4.20 (br s, 1 hr, NC*H*HCH~2~), 3.44 (dt, *J* = 11.0, 3.5 Hz, 1 hr, C*H*HOH), 3.26 (dt, *J* = 11.3, 5.8 Hz, 1 hr, CH*H*OH), 2.87--2.63 (m, 2 hr, NCH*H*CHCH~2~OH, NCH*H*CH~2~), 2.51 (td, *J* = 10.2, 5.2 Hz, 1 hr, CHAr), 1.87--1.72 (m, 2 hr, C*H*CH~2~OH, NCH~2~C*H*H), 1.71--1.58 (m, 2 hr, NCH~2~CH*H*, OH), 1.49 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (101 MHz, CDCl~3~, 298 K, observed as a mixture of rotamers) δ 154.8 (C = O), 143.5 (C~Ar~ quat), 137.7 (2 × C~Ar~), 129.5 (2 × C~Ar~), 91.7 (IC~Ar~ quat), 79.7 (*C*(CH~3~)~3~), 63.0 (*C*H~2~OH), 46.4 (br m, N*C*H~2~CHCH~2~OH), 44.4 and 43.5 (N*C*H~2~CH~2~, *C*HAr, *C*HCH~2~OH), 33.8 (NCH~2~*C*H~2~), 28.5 (C(*C*H~3~)~3~);

HRMS (ESI^+^) *m/z* Calculated for C~17~H~25~NO~3~^127^I \[M+H\] 418.0879; Found 418.0886.

HPLC Conditions: Chiralpak ID 3-column, 90:10 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 230.1 nm. Retention times: 6.7 min (3*R,*4*S* enantiomer), 7.4 min (3*S,*4*R* enantiomer).

SMILES: IC1 = CC = C(\[C@\@H\]2\[C@\@H\](CO)CN(C(OC(C)(C)C)=O)CC2)C = C1

InChI = 1S/C17H24INO3/c1-17(2,3)22-16(21)19-9-8-15(13(10-19)11--20)12-4-6-14(18)7-5-12/h4-7,13,15,20H,8--11 H2,1--3 H3/t13-,15-/m1/s1

![*tert*-Butyl (--)-(*3S,4R*)−4-(4-iodophenyl)−3-(hydroxymethyl)piperidine-1-carboxylate ((--)−8b) .](elife-56427-app1-fig13){#app1chem13}

A flame-dried round-bottom flask was charged with amide (+)−7b (558 mg, 1.00 mmol, one equiv), followed by di-*tert*-butyl dicarbonate (Boc~2~O, 873 mg, 4.00 mmol, four equiv) and 4-(dimethylamino)pyridine (DMAP, 24.4 mg, 0.20 mmol, 20 mol %). The reaction vessel was sealed with an aluminum cap (with molded butyl septa) and purged with argon, then anhydrous MeCN (3.3 mL) and anhydrous CH~2~Cl~2~ (0.5 mL) were added by syringe. The mixture (0.3 M) was then stirred at 40°C for 22 hr. The reaction mixture was then allowed to cool to rt and sat. aq. NH~4~Cl (5 mL) and CH~2~Cl~2~ (5 mL) were added. The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure to afford the crude *N*-Boc protected piperidine derivative.

This crude solubilized in anhydrous THF (3.5 mL, 0.3 M) and the resulting solution was added dropwise to a suspension of LiAlH~4~ (75.9 mg, 2.00 mmol, two equiv) in anhydrous THF (1.5 mL, 1.0 M) at 0°C under argon atmosphere. The mixture was then stirred at 20°C for 30 min. The reaction mixture was then quenched by slow addition of sat. aq. NH~4~Cl (5 mL) at 0°C and stirred at rt for 30 min. The resulting suspension was filtered through a pad of Celite, eluting with EtOAc (3 × 10 mL). The phases were separated, and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. Purification by flash column chromatography (10% to 15% acetone/pentane) afforded primary alcohol (--)−8b as a white solid (315 mg, 68% over two steps, 98.0% *ee*, containing approx. 15% deiodinated derivative).

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 8.0 (*c* 1.0, CHCl~3~).

Characterization data identical to that reported for enantiomeric alcohol (+)-S4b (see S27).

HPLC Conditions: Chiralpak ID 3-column, 90:10 *n*-hexane:*i*-PrOH, flow rate: 1 mL·min^--1^, 35°C, UV detection wavelength: 230.1 nm. Retention times: 6.7 min (3*R,*4*S* enantiomer), 7.4 min (3*S,*4*R* enantiomer).

SMILES: IC1 = CC = C(\[C\@H\]2\[C\@H\](CO)CN(C(OC(C)(C)C)=O)CC2)C = C1

InChI = 1S/C17H24INO3/c1-17(2,3)22-16(21)19-9-8-15(13(10-19)11--20)12-4-6-14(18)7-5-12/h4-7,13,15,20H,8--11 H2,1--3 H3/t13-,15-/m0/s1

![*tert*-Butyl (3*S*,4*R*)−3-((benzo\[d\]\[1,3\]dioxol-5-yloxy)methyl)−4-(4-iodophenyl)piperidine-1-carboxylate ((--)−9b) Alcohol (--)−8b (203 mg, 0.49 mmol, one equiv) and triethylamine (96 μL, 0.69 mmol, 1.4 equiv) were added to a flame-dried round-bottom flask, dissolved in anhydrous CH~2~Cl~2~ (2.5 mL, 0.2 M) and cooled down to 0°C.\
Methanesulfonyl chloride (49 μL, 0.64 mmol, 1.3 equiv) was then added by Gilson pipette. After stirring 5 min at 0°C, the reaction mixture was stirred at 25°C for 2 hr, then diluted with CH~2~Cl~2~ (5 mL) and sat. aq. NaHCO~3~ (5 mL). The phases were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure to afford the crude mesylated alcohol derivative.](elife-56427-app1-fig14){#app1chem14}

NaH (60% dispersion in mineral oil, 45.2 mg, 1.10 mmol, 2.2 equiv) was added to a solution of sesamol (135 mg, 0.98 mmol, two equiv) in anhydrous DMF (3.0 mL, 0.3 M) at 0°C. The mixture was then stirred at 25°C for 1 hr. A solution of the crude mesylated alcohol in dry DMF (2.0 mL, 0.2 M) was then added dropwise to this suspension. The resulting mixture was stirred at 90°C for 20 hr. The reaction mixture was quenched by addition of H~2~O (5 mL) and aq NaOH 1 N (5 mL) and EtOAc (10 mL) were then added. The phases were separated, and the aqueous layer was extracted with EtOAc (4 × 20 mL). The combined organic extracts were washed with brine (2 × 50 mL), dried over Na~2~SO~4~ and filtered. The solvent was removed under reduced pressure. Purification by flash column chromatography (5% acetone/pentane) afforded piperidine (--)−9b as a white solid (188 mg, 71% over two steps).

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 43.3 (*c* 1.2, CHCl~3~).

R~f~0.15 (5% acetone/pentane); mp = 51--54°C; ν~max~ (film)/cm^--1^ 2919, 1685 (C = O), 1483, 1424, 1230, 1163, 1129, 1036, 1106, 928, 813, 764; ^1^H NMR (400 MHz, CDCl~3~, 298 K) δ 7.65--7.59 (m, 2 hr, HC~Ar~), 6.67--6.91 (m, 2 hr, HC~Ar~), 6.64 (d, *J* = 8.4 Hz, 1 hr, HC~Ar~), 6.36 (d, *J* = 2.5 Hz, 1 hr, HC~Ar~), 6.14 (dd, *J* = 8.5, 2.5 Hz, 1 hr, HC~Ar~), 5.89 (s, 2 hr, OCH~2~O), 4.43 (br s, 1 hr, NC*H*HCHCH~2~OAr), 4.25 (br s, 1 hr, NC*H*HCH~2~), 3.61 (dd, *J* = 9.4, 2.9 Hz, 1 hr, C*H*HOAr), 3.45 (dd, *J* = 9.4, 6.4 Hz, 1 hr, CH*H*OAr), 2.91--2.71 (br m, 2 hr, NCH*H*CHCH~2~OAr, NCH*H*CH~2~), 2.65 (td, *J* = 11.8, 3.8 Hz, 1 hr, CHAr), 2.08--1.96 (br m, 1 hr, C*H*CH~2~OAr), 1.86--1.76 (br m, 1 hr, NCH~2~C*H*H), 1.76--1.63 (m, 1 hr, NCH~2~CH*H*), 1.50 (s, 9 hr, C(CH~3~)~3~);

^13^C NMR (101 MHz, CDCl~3~, 298 K) δ 154.7 (C = O), 154.2 (OC~Ar~ quat), 148.1 (OC~Ar~ quat), 143.1 (C~Ar~ quat), 141.7 (OC~Ar~ quat), 137.7 (2 × C~Ar~), 129.4 (2 × C~Ar~), 107.8 (C~Ar~), 105.5 (C~Ar~), 101.1 (OCH~2~O), 98.0 (C~Ar~), 91.8 (IC~Ar~ quat), 79.7 (*C*(CH~3~)~3~), 68.7 (*C*H~2~OAr), 47.0 (br m, N*C*H~2~CHCH~2~OAr), 44.3 (N*C*H~2~CH~2~, *C*HAr), 41.6 (*C*HCH~2~OAr), 33.6 (NCH~2~*C*H~2~), 28.4 (C(*C*H~3~)~3~);

HRMS (ESI^+^) *m/z* Calculated for C~24~H~29~NO~5~^127^I \[M+H\] 538.1090; Found 538.1104.

SMILES: IC1 = CC = C(\[C\@H\]2\[C\@H\](COC3 = CC(OCO4)=C4C = C3)CN(C(OC(C)(C)C)=O)CC2)C = C1.

InChI = 1S/C24H28INO5/c1-24(2,3)31-23(27)26-11-10-20(16-4-6-18(25)7-5-16)17(13-26)14-28-19-8-9-21-22(12-19)30-15-29-21/h4-9,12,17,20H,10--11,13-15H2,1--3 H3/t17-,20-/m0/s1.

![(3*S*,4*R*)−3-((Benzo\[d\]\[1,3\]dioxol-5-yloxy)methyl)−4-(4-iodophenyl)piperidine-1-ium chloride.\
(3 ∙ HCl) 4 N HCl in 1,4-dioxane (250 μL, 1.00 mmol, 10 equiv) was added to a solution of *N-*Boc protected piperidine (--)−9b (56.9 mg, 0.10 mmol) in 1,4-dioxane (250 μL, 0.4 M). At 0°C under air. The solution was stirred at 25°C for 18 hr, then an ice-cold 1:1 mixture of Et~2~O/pentane (1 mL) was added and formation of a solid precipitate was observed. This was filtered and washed with further ice-cold Et~2~O/pentane mixture (2 × 5 mL). The solid precipitate was dried under reduced pressure to afford (3*S*,4*R*)−3-((benzo\[d\]\[1,3\]dioxol-5-yloxy)methyl)−4-(4-iodophenyl)piperidine-1-ium chloride 3 ∙ HCl (38.5 mg, 81%) as an off-white solid.](elife-56427-app1-fig15){#app1chem15}

-- $\left\lbrack \alpha \right\rbrack_{D}^{23}$ 86.0 (*c* 0.9, MeOH). mp = 203--205 °C;

ν~max~ (film)/cm^--1^3321 (NH), 2926, 2807, 1618, 1484, 1185, 1103, 1033, 1003, 932, 846, 813, 787;

^1^H NMR (400 MHz, CD~3~OD, 298 K) δ 7.71--7.64 (m, 2 hr, HC~Ar~), 7.11--7.04 (m, 2 hr, HC~Ar~), 6.63 (d, *J* = 8.5 Hz, 1 hr, HC~Ar~), 6.39 (d, *J* = 2.5 Hz, 1 hr, HC~Ar~), 6.18 (dd, *J* = 8.5, 2.5 Hz, 1 hr, HC~Ar~), 5.89--5.82 (m, 2 hr, OCH~2~O), 3.71--3.62 (m, 2 hr, C*H*HOAr, NC*H*HCHCH~2~OAr), 3.60--3.48 (m, 2 hr, CH*H*OAr, NC*H*HCH~2~), 2.21--2.11 (m, 2 hr, NCH*H*CHCH~2~OAr, NCH*H*CH~2~), 3.00--2.90 (m, 1 hr, CHAr), 2.49--2.37 (m, 1 hr, C*H*CH~2~OAr), 2.09--2.00 (m, 2 hr, NCH~2~C*H*~2~);

^13^C NMR (101 MHz, CD~3~OD, 298 K) δ 155.2 (OC~Ar~ quat), 149.7 (OC~Ar~ quat), 143.5 (C~Ar~ quat), 143.0 (OC~Ar~ quat), 139.1 (2 × C~Ar~), 130.7 (2 × C~Ar~), 108.8 (C~Ar~), 106.6 (C~Ar~), 102.5 (OCH~2~O), 98.9 (C~Ar~), 93.1 (IC~Ar~ quat), 68.9 (*C*H~2~OAr), 47.7 (N*C*H~2~CHCH~2~OAr), 45.4 (N*C*H~2~CH~2~), 43.0 (*C*HAr), 40.5 (*C*HCH~2~OAr), 31.3 (NCH~2~*C*H~2~);

HRMS (ESI^+^) *m/z* Calculated for C~19~H~21~NO~3~^127^I \[M--Cl\] 438.0566; Found 438.0571.

SMILES: IC1 = CC = C(\[C\@H\]2\[C\@H\](COC3 = CC(OCO4)=C4C = C3)CNCC2)C = C1 .Cl.

InChI = 1S/C19H20INO3.ClH/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;/h1-6,9,14,17,21H,7--8,10-12H2;1H/t14-,17-;/m0./s1.
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Editors and reviewers were impressed by the scope and detail of your examination of the mode by which the human serotonin transporter recognizes paroxetine, a high-affinity antidepressant. The conclusions reached through this multi-faceted analysis constitute a significant advancement in an exciting field at the interface between membrane physiology and neurobiology.

**Decision letter after peer review:**

Thank you for submitting your article \"Chemical and structural investigation of the paroxetine-human serotonin transporter complex\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Lucy Forrest as the Reviewing Editor and by José Faraldo-Gómez as the Senior Editor. Reviewers \#2 and \#3 have agreed to reveal their identity: Poul Nissen and Amy Newman, respectively. Based on the reviewers\' comments, included below, and on subsequent discussions among reviewers and editors, I am glad to inform you that we believe that your manuscript is potentially suitable for publication in *eLife*, provided you make a number of revisions to address the reviewers\' concerns and recommendations, to the extent possible.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data. Our hope is that authors will eventually carry out those additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Reviewer \#1:

The manuscript by Gouaux and colleagues contains an analysis of the binding arrangement of the highest-affinity antidepressant, paroxetine, to human serotonin transporter. This ligand has been the subject of a number of previous studies, which suggested that it might adopt one of two alternate arrangements the so-called ABC and ACB poses, in which the two arms of the v-shaped ligand are flipped between the \"B\" and \"C\" sub-sites of the central binding site. Prior X-ray crystallographic data however, was limited by the fact that the protein constructs used were of mutants than were modified in key locations.

The combination of cryo-EM, x-ray structural analysis with synthesis of brominated and iodinated compounds, binding (\*Citalopram competition) and 5HT uptake assays is impressive. Anomalous diffraction identifies some signal for the halogenated group in the location consistent with the ABC pose; however, computational analyses by Abagayan suggested the bromination itself tends to favor this pose. The most compelling data therefore comes from the \~3.3Å cryo-EM structures of the wild-type protein bound to paroxetine, which indicate differences in the correlation coefficient for fitting the ligand in the two orientations. Unfortunately, at this resolution, I believe this data cannot be used to rule out the possibility that both orientations are occupied, especially if ACB has a lower occupancy.

I conclude that these data are further suggestive of the ABC pose being the primary arrangement, but do not categorically rule out that paroxetine also adopts the ACB pose.

Major comments:

1\) The anomalous diffraction densities are poorly defined (at 4 sigma), albeit appearing in the general region expected for the position of paroxetine that the authors identify. I am also concerned by the large fraction of residues that are defined as containing a poor fit to the EM map (all-atom inclusion \<40%). Is this some kind of model bias, because of using the previously obtained X-ray structures as starting points for refinement? (MR using 6AWN = S439T/3.6Å).

2\) Discussion paragraph four starting: \"Paroxetine is stabilized\...\". These arguments read as self-fulfilling. Close contact in a structure does not mean that all interactions are stabilizing; it neglects entropic contributions and the fact that some contacts may be disfavored in order to optimize the overall free energy. Perhaps it would be useful to separate the descriptions of the interactions with the discussion of the nature of the ABC and ACB orientations. For example, the arguments regarding the ABC and ACB orientations seem to relate to the presence of aromatic groups and hydrogen-bonding of the benzodioxol and fluorophenyl moieties; but wouldn\'t both types of interactions be present also in the ACB mode? Similarly, why are differences in electronegativity between C-F, C-Br and C-I more relevant for subsite C rather than subsite B?

3\) Remarkably, and somewhat disturbingly, in the new cryo-EM structures the tail of DDM protrudes between helices TM11/10 and TM12, which are in turn more separated. How is it possible that the same tail is not observed/modelled in any of the previous X-ray structures, even though the maltose group is modeled in the same position in e.g. 6AWN? This discrepancy should be described and mentioned in the Results when comparing the cryo-EM and x-ray structures.

Reviewer \#2:

Coleman et al. present a study of paroxetine (pax) binding investigated with different methods (single-particle cryo-EM, X-ray crystallography, binding studies) using five different constructs of SERT -- i) wild-type with C-term GFP, ii) ts2 active with Ile291Ala, Thr439Ser and C-term GFP, iii) same ts2 active with in addition Asn177 mutations, iv) inactive ts2 with Tyr110Ala, Ile291Ala and v) ΔN72, ΔC13 SERT plus an antibody 8B6. They investigate the binding of Br- and I-pax derivatives (Br and I substituting F in the fluorophenyl-group of pax), the synthesis of which is also described here. These derivative compounds bind and inhibit SERT, although with a somewhat reduced affinity (going from low to high nM range). Crystal structures and cryo-EM structures of different construct and complexes are overall very consistent on how pax binds to SERT.

The study is motivated by ambiguities in the literature on how pax binds, represented by ABC or ACB poses to subsites A,B, and C at the central site of SERT. Earlier structural studies also from the Gouaux lab as well as the new studies presented here show the ABC pose, while docking studies and MD simulation from the Shi group indicate a more dynamic binding mode featuring both ABC and ACB poses that through proposed entropy effects for the pseudosymmetry of pax would explain a high affinity. The study presented in this manuscript is important and relevant to a large readership, and to applied uses of the structural information for further drug development.

Subsite A of SERT binds an amine functionality, here the piperidine ring of pax. The B asubsite attracts bulky groups with electronegative substituents such as halogenated aromatic groups, catecholes and the benzodioxol group of pax. Site C occupies other groups, in pax a halogenated aromatic group (fluoro-phenyl). Pax thus has two aromatic/heterocylic groups with electronegative substituents -- the fluoro-phenyl group and the benzodioxol, and according to the structural studies the benzodioxol \"wins\" the B-subsite. Studies of the ABC vs. ACB pose dynamics through derivative compounds should perturb the balance of how the two subsites B and C are occupied -- e.g. by making the benzodioxol group bind weaker to the B-subsite or the fluorophenyl group potentially binding stronger to it. The study design however decreases the electronegativity of the fluorophenyl group by substituting F for Br or I -- this will presumably make it bind weaker to both subsites B and C. The structures, therefore, and perhaps not surprisingly, confirm the ABC pose found in earlier structural studies. Studies of Asn177 mutants in the ts2 active background show similar consistency to this binding mode and the study leaves little doubt that the ABC pose may be a dominating pose.

Another question has been raised on the use of the thermostabilizing mutation Thr439Ser, which according to the Shi group obscures the dynamic nature of pax binding by ABC/ACB poses and again the authors find no major differences based on this mutant form.

Major points

1\) It is rather difficult to keep track of the SERT constructs used throughout the report -- please include/add a table and perhaps also a figure that the reader can refer to and be careful that the text is always clear on which construct is now described/discussed

2\) It may be argued that the study design does not really challenge the ambiguity of earlier studies. It would be critical to include other pax derivatives, eg. some that reduce the electronegativity of heteroatoms of the benzodioxol group, which will then likely loose affinity to the subset B, or that increase the B-subsite affinity of the fluoro-phenyl group (e.g. as a 3,4-difluorophenyl).

Alternatively, the manuscript must be rewritten into a report that confirms the ABC pose of pax observed under the given set of conditions -- that rather than opposing the ACB pose model.

3\) The cryo-EM structures represent only a small fraction of total particles in the cryo-EM data sets (about 10%). What else is observed from the remaining 90% of the datasets? Could other classes of the cryo-EM study of ΔN72, ΔC13 represent more flexible structures with ACB poses of pax?

4\) The anomalous difference map analysis is scarcely described and therefore difficult to review. Anomalous difference maps must be carefully assessed to obtain a maximal signal-noise ratio, which on the other hand is crucial for any statements to be made on the absence of minor sites (which will disappear in the noise of a suboptimal fourier analysis). The S/N ratio might for example (conveniently) be assessed by a comparison of the highest positive (signal) compared to the highest negative peaks (noise) in a map. Table 4 indicate that the resolution of the data has been stretched to a maximum (and remains low resolution), and that atomic models have been refined against these very low resolution data for Br-pax and I-pax (compared to the earlier ts3-pax data at 3.14 Å resolution in a similar crystal form). Reading from the manuscript, model phases have been derived then from these low-resolution refined structures and used for the anomalous difference Fourier map. This is not necessarily the way to get the highest S/N ratio, where higher quality model phases from a higher-resolution isomorphous structure can also be applied, perhaps combined with an appropriate blurring of the phases at higher resolution by a negative temperature factor approach -- this must be tested. Furthermore, the exact choice of resolution of the input anomalous data must be established by trial-and-error searching again for the maximal S/N ratio of the anomalous difference map, and also other parameters (such as a maximum threshold allowed for F+/-F- differences). The maps must be shown for both subsites B and C

5\) All paroxetine crystal forms seem more or less isomorphous -- an isomorphous difference Fourier map analysis (Fo-Fo maps) would be very useful, and will often show minor sites well. Any relevant isomorphous pair of paroxetine crystals (Br-pax/pax; Br-pax/I-pax, I-pax/pax) should be analysed. Again, the model phases used for the Fourier analysis should be selected carefully and probably come from the higher resolution \"native pax structure\". Similar to the anomalous difference maps, the isomorphous difference maps must be shown for subsites B and C

Reviewer \#3:

The authors combined a novel chemical synthesis of previously described Br-paroxetine and its I-analogue, cryo-EM, and crystallography to further probe the SSRI paroxetine binding pose at the central site of SERT. While the experimental design and the data collection are solid, the deduction toward the conclusion does not entirely resolve the controversy originally described in the Introduction for paroxetine itself.

Substantive but addressable concerns:

1\) Overall the cryo-EM structures are of low resolution and the authors could not \"identify features associated with the scattering of bromine and iodine\". The crystal structures in the \"ts2-inactive\" background are of even lower resolutions (4.69 and 6.12Å), though there were \"clear density for Br- and I- atoms of the paroxetine derivatives in subsite C\". Thus, given that the CC of ACB pose, 0.70, is not unacceptably low, there is no definitive evidence presented to specifically argue for the ABC and against the ACB pose. In addition, as -F to -Br and -I may significantly change the properties of the compound (see Abramyan, et al., 2018), it is not safe to assume that Br- or I-paroxetine are in the same pose as paroxetine. See https://www.ncbi.nlm.nih.gov/pubmed/27982595. Indeed, it is difficult for the cryo-EM and X-ray crystallography work to consider dynamics, thus the authors should not completely exclude the possibility of an ACB pose (see Discussion).

2\) Importantly, there appear to be some misinterpretations of the studies described in Abramyan et al., 2018 and Slack et al., 2019, that must be addressed:

• \"However, recent mutagenesis, molecular dynamics, and binding studies with paroxetine analogues suggest that paroxetine may occupy two distinct poses in which the benzodioxol and fluorophenyl groups reside in subsite B or C, depending on the rotameric position of Phe341 and the presence of the thermostabilizing mutation Thr439Ser18,20 (ACB pose, Figure 1C).\" The main points in Abramyan et al., 2018 and Slack et al., 2019, were that the favored entropy component may play a significant role in paroxetine\'s high affinity, which include the dynamics in the S1 site (e.g., the dynamics of Phe341 in the presence of paroxetine but not Br-paroxetine) and potential pose ambiguity. The mutations may disrupt such dynamics but not necessarily associated with a specific pose.

• Regarding the synthesis of Br- and I-paroxetine analogues, this alternative approach is indeed new, however the authors should acknowledge that Br-paroxetine was previously synthesized and fully characterized in Slack et al., 2019.

• \"In this study, the authors hypothesized that the difference could be because of the crystallization conditions and thermostabilizing mutations.\" It is not clear what \"this study\" is referring to. Davis et al., 2016, did not discuss the crystal structures, while Abramyan et al did not hypothesize that WT should be in the ACB pose (see above).

• Importantly, the dominant occupation of Br-paroxetine in the ABC pose is consistent with the findings in Slack et al., 2019 and should be acknowledged, as the studies in the present report for this compound were why it was synthesized in the first place. Based on the molecular dynamics studies in Abramyan et al, the studies in the present report neither support nor refute that paroxetine may bind in either pose in the native hSERT.

10.7554/eLife.56427.sa2

Author response

> Reviewer \#1:
>
> The manuscript by Gouaux and colleagues contains an analysis of the binding arrangement of the highest-affinity antidepressant, paroxetine, to human serotonin transporter. This ligand has been the subject of a number of previous studies, which suggested that it might adopt one of two alternate arrangements the so-called ABC and ACB poses, in which the two arms of the v-shaped ligand are flipped between the \"B\" and \"C\" sub-sites of the central binding site. Prior X-ray crystallographic data however, was limited by the fact that the protein constructs used were of mutants than were modified in key locations.
>
> The combination of cryo-EM, x-ray structural analysis with synthesis of brominated and iodinated compounds, binding (\*Citalopram competition) and 5HT uptake assays is impressive. Anomalous diffraction identifies some signal for the halogenated group in the location consistent with the ABC pose; however, computational analyses by Abagayan suggested the bromination itself tends to favor this pose.

We have added a sentence about the computational analysis of Abagayan, see "These studies also suggested that bromination of paroxetine and certain mutations near the central site, such as Ala169Asp, favored ABC pose." While we agree with the reviewer that a stronger anomalous difference peak would have been helpful toward understanding if the ACB pose is present at low occupancy, the observed density in subsite C for the halogens is substantial. Based on comments from reviewer \#2 we have increased the signal-to-noise ratio of the anomalous maps and also have provided isomorphous difference maps which further support the ABC pose as being the favored pose for paroxetine and the analogues investigated in this work.

> The most compelling data therefore comes from the \~3.3Å cryo-EM structures of the wild-type protein bound to paroxetine, which indicate differences in the correlation coefficient for fitting the ligand in the two orientations. Unfortunately, at this resolution, I believe this data cannot be used to rule out the possibility that both orientations are occupied, especially if ACB has a lower occupancy.

We have not ruled out the ACB pose and have revised the manuscript to make it clear that the ACB pose could be present at an occupancy that is not discernible at the present resolution.

> I conclude that these data are further suggestive of the ABC pose being the primary arrangement, but do not categorically rule out that paroxetine also adopts the ACB pose.

As mentioned above, we agreed with the reviewer that our data does not rule out the ACB pose but rather supports the conclusion that the ABC pose is the dominant pose.

> Major comments:
>
> 1\) The anomalous diffraction densities are poorly defined (at 4 sigma), albeit appearing in the general region expected for the position of paroxetine that the authors identify. I am also concerned by the large fraction of residues that are defined as containing a poor fit to the EM map (all-atom inclusion \<40%). Is this some kind of model bias, because of using the previously obtained X-ray structures as starting points for refinement? (MR using 6AWN = S439T/3.6Å).

Considering the resolution of Br-paroxetine and I-paroxetine structures, the fact that the highest anomalous difference peak goes beyond 4σ is meaningful. The Br- peak is now at 6.0σ and I- peak is at 4.5σ. We would like to draw the reviewer's attention to Figure 4---figure supplement 5, which shows that most residues fit the density well. The low all-atom inclusion score is because of unmodeled micelle density and the unmodeled constant domain of Fab.

> 2\) Discussion paragraph four starting: \"Paroxetine is stabilized...\". These arguments read as self-fulfilling. Close contact in a structure does not mean that all interactions are stabilizing; it neglects entropic contributions and the fact that some contacts may be disfavored in order to optimize the overall free energy. Perhaps it would be useful to separate the descriptions of the interactions with the discussion of the nature of the ABC and ACB orientations. For example, the arguments regarding the ABC and ACB orientations seem to relate to the presence of aromatic groups and hydrogen-bonding of the benzodioxol and fluorophenyl moieties; but wouldn\'t both types of interactions be present also in the ACB mode? Similarly, why are differences in electronegativity between C-F, C-Br and C-I more relevant for subsite C rather than subsite B?

We acknowledge that these interactions, in a broad sense, could be possible in both poses. However, we observe that there also would be significant changes in the distances of many interactions upon modeling paroxetine in the ACB vs. the ABC pose. The differences in electronegativity and carbon-halogen bond length are relevant to understand the differences in affinities of paroxetine derivatives irrespective of the pose. The Discussion section has been revised to reflect these views.

> 3\) Remarkably, and somewhat disturbingly, in the new cryo-EM structures the tail of DDM protrudes between helices TM11/10 and TM12, which are in turn more separated. How is it possible that the same tail is not observed/modelled in any of the previous X-ray structures, even though the maltose group is modeled in the same position in e.g. 6AWN? This discrepancy should be described and mentioned in the Results when comparing the cryo-EM and x-ray structures.

The head group positioning in the x-ray structures suggests that the tail group of detergent would have extended into the space between TM10, 11, and 12. However, the tail was not modeled because of lack of density in the x-ray structure. Differences in the way maps are obtained and in the experimental conditions (i.e. DDM vs. OM) in both experiments make it possible that the same feature, such as a detergent tail, is visible in the EM map but not in the xray map. We have added a statement describing the differences between likely detergent density in the cryo-EM and x-ray structures: "In the cryo-EM maps, the maltose headgroup of a DDM molecule could also be visualized in the allosteric site with the detergent tail inserted between TMs 10, 11, and 12. In contrast, in the x-ray maps only the head group of the octyl-maltoside detergent could be modeled due to the weak density of the hydrocarbon chain."

We also note that the conformations of TMs 10, 11, and 12 are similar to their respective conformations in other outward-open SERT structures solved by cryo-EM. Please see Figure 5.

> Reviewer \#2:
>
> \[...\]
>
> Major points
>
> 1\) It is rather difficult to keep track of the SERT constructs used throughout the report -- please include/add a table and perhaps also a figure that the reader can refer to and be careful that the text is always clear on which construct is now described/discussed.

Table 1 has been added in the revised version of the manuscript describing the SERT variants used in this study.

> 2\) It may be argued that the study design does not really challenge the ambiguity of earlier studies. It would be critical to include other pax derivatives, eg. some that reduce the electronegativity of heteroatoms of the benzodioxol group, which will then likely loose affinity to the subset B, or that increase the B-subsite affinity of the fluoro-phenyl group (e.g. as a 3,4-difluorophenyl).
>
> Alternatively, the manuscript must be rewritten into a report that confirms the ABC pose of pax observed under the given set of conditions -- that rather than opposing the ACB pose model.

We appreciate reviewer's insights on the manuscript. However, structural studies involving other derivatives of paroxetine are beyond the scope of this manuscript. The data that we have presented in the manuscript demonstrates that under the examined conditions, the ABC pose of paroxetine is favored over the ACB pose. However, we agree with reviewer that we cannot exclude the possibility of ACB pose. The manuscript has been rephrased accordingly.

> 3\) The cryo-EM structures represent only a small fraction of total particles in the cryo-EM data sets (about 10%). What else is observed from the remaining 90% of the datasets? Could other classes of the cryo-EM study of ΔN72, ΔC13 represent more flexible structures with ACB poses of pax?

The particle picking was carried out using two different methods -- DoG-picker and blobbased picking in cryoSPARC, which both resulted in about 2 million picks. Most of these picks are not SERT particles. When we performed 2D classification on the picks that were discarded, we found that they did not have any features of SERT-Fab complexes. We sorted the picks by different methods using 3D and 2D classification and then combined them for refinement. About 120K particles were removed using 3D classification for the paroxetine data set because reconstructions derived from these particles were poorly resolved and it was not possible to observe a density feature for paroxetine. It is possible that these particles are more flexible with an ACB pose, though it is also likely that they did not produce higher resolution reconstructions due to other factors such as denaturation at the air-water interface, thick or poor quality ice, or difficulties in determination of accurate particles parameters. The final particle set has 420K particles for paroxetine, which is about 20% of the total picks, a similar percentage of the total picks across all three data sets.

For the Br and I-paroxetine data sets, all the particles which resembled SERT-Fab from 2D were used in refinement. Hence, we believe that the final dataset is a good representation of the major conformation seen in the dataset. We do agree that in the classes that were excluded during 2D and 3D classification steps that it is still possible that some of the discarded particles were more flexible with an ACB pose of paroxetine at the central site. However, the excluded classes were poorly resolved, hence making any high-resolution inferences from them ambiguous. Owing to this possibility we rephrased certain portions of the manuscript to allow for the possibility of ACB pose.

"We observed that in the ACB pose, paroxetine could be positioned with a CC of 0.70 compared with 0.84 for the ABC pose suggesting that while ABC pose is clearly preferred under the conditions we tested, the possibility of an ACB pose cannot be excluded (Figure 4---figure supplementary 5A,B)."

See also:

"However, the data presented in the manuscript does not completely exclude the possibility of an ACB pose at the central site."

> 4\) The anomalous difference map analysis is scarcely described and therefore difficult to review. Anomalous difference maps must be carefully assessed to obtain a maximal signal-noise ratio, which on the other hand is crucial for any statements to be made on the absence of minor sites (which will disappear in the noise of a suboptimal fourier analysis). The S/N ratio might for example (conveniently) be assessed by a comparison of the highest positive (signal) compared to the highest negative peaks (noise) in a map. Table 4 indicate that the resolution of the data has been stretched to a maximum (and remains low resolution), and that atomic models have been refined against these very low resolution data for Br-pax and I-pax (compared to the earlier ts3-pax data at 3.14 Å resolution in a similar crystal form). Reading from the manuscript, model phases have been derived then from these low-resolution refined structures and used for the anomalous difference Fourier map. This is not necessarily the way to get the highest S/N ratio, where higher quality model phases from a higher-resolution isomorphous structure can also be applied, perhaps combined with an appropriate blurring of the phases at higher resolution by a negative temperature factor approach -- this must be tested. Furthermore, the exact choice of resolution of the input anomalous data must be established by trial-and-error searching again for the maximal S/N ratio of the anomalous difference map, and also other parameters (such as a maximum threshold allowed for F+/-F- differences). The maps must be shown for both subsites B and C

We thank the reviewer for these suggestions. Although we had already performed many of these analyses to improve the S/N ratio of the anomalous maps in the initial submission, we had not described what we had done in sufficient detail. Furthermore, we had not tried to blur the phases at higher resolution, this was a helpful suggestion and improved the quality of the Brparoxetine map substantially (maximum peak intensity 5.5 vs. 6.0σ). We have also written a paragraph in the Materials and methods section to describe what we have done in more detail:

"Anomalous difference maps

X-ray data sets were processed with XDS; Friedel pairs were allowed to have different intensities. Molecular replacement was performed with coordinates from the previously determined ts2-inactive SERT-paroxetine structure (Protein Data Bank (PDB) code: 6AWN) using PHASER. B-factors were refined using PHENIX followed by generating anomalous difference maps using the phases derived from the higher resolution structures. To maximize the signal-to-noise ratio of the Br-paroxetine anomalous difference density, the high-resolution phases were blurred with a B-factor of 500 with a high-resolution cutoff of 5.5 Å. Using these optimized parameters for the Fourier analysis of the Br-paroxetine diffraction data, we obtained an anomalous map with the largest difference peak being present at 6.0σ and the noise level estimated at \~2.5σ. To maximize the signal-noise-ratio of the I-paroxetine anomalous difference density, a high-resolution and low-resolution cutoff of 6.3 and 30 Å was applied during the generation of the anomalous maps. Using these optimized parameters for the Fourier analysis of the I-paroxetine diffraction data, we obtained an anomalous map with the largest difference peak being present at 4.5σ and the noise level estimated at \~2.5σ."

> 5\) All paroxetine crystal forms seem more or less isomorphous -- an isomorphous difference Fourier map analysis (Fo-Fo maps) would be very useful, and will often show minor sites well. Any relevant isomorphous pair of paroxetine crystals (Br-pax/pax; Br-pax/I-pax, I-pax/pax) should be analysed. Again, the model phases used for the Fourier analysis should be selected carefully and probably come from the higher resolution \"native pax structure\". Similar to the anomalous difference maps, the isomorphous difference maps must be shown for subsites B and C

We appreciate this constructive suggestion. The paroxetine crystal forms are indeed fairly isomorphous with \<1% difference in unit cell dimensions. When we analyzed the suggested Fo(paroxetine)-Fo(Br-paroxetine) and Fo(paroxetine)-Fo(I-paroxetine) maps, we found that they did contain density features of the halogens. The Fo(Br-paroxetine)-Fo(I-paroxetine) maps, did not have meaningful features, perhaps because of the low resolution of both datasets. Like the anomalous difference maps, we have also shown both subsite B and C in Figure 4---figure supplement 6 and have displayed the difference density with a radius covering subsite B and C. We added the following text:

"Next, we calculated isomorphous difference maps (F~o~-F~o~) using the ts2-inactive paroxetine dataset (PDB: 6AWN) and either the Br-paroxetine or I-paroxetine datasets. The F~o~(paroxetine)F~o~(Br-paroxetine) map also revealed a difference peak in subsite C near the halogenated groups while no significant peaks were detected in subsite B (Figure 4---figure supplement 6A). Similarly, the F~o~(paroxetine)-F~o~(I-paroxetine) map also contained a difference peak which overlapped with the position of the halogen (Figure 4---figure supplement 6B) while the F~o~(Brparoxetine)-F~o~(I-paroxetine) difference map did not contain any interpretable features, likely due to the low resolution of both datasets (Figure 4---figure supplement 6C)."

We have added a section in the Materials and methods to describe in detail how this analysis was performed,

**"**Fo-Fo isomorphous difference maps

Isomorphous difference (F~o~-F~o~) maps were calculated in PHENIX by analyzing isomorphous pairs of crystals. Difference maps were calculated using the previously determined ts2-inactive SERT-paroxetine dataset and PDB (6AWN) for phasing. High- and low-resolution cutoffs of 6.0 and 30.0 Å were applied for the F~o~(paroxetine)- F~o~(Br-paroxetine) map and cutoffs of 6.3 and 30.0 Å were used for the F~o~(paroxetine)- F~o~(I-paroxetine) and F~o~(Br-paroxetine)- F~o~(Iparoxetine) maps."

> Reviewer \#3:
>
> The authors combined a novel chemical synthesis of previously described Br-paroxetine and its I-analogue, cryo-EM, and crystallography to further probe the SSRI paroxetine binding pose at the central site of SERT. While the experimental design and the data collection are solid, the deduction toward the conclusion does not entirely resolve the controversy originally described in the Introduction for paroxetine itself.
>
> Substantive but addressable concerns:
>
> 1\) Overall the cryo-EM structures are of low resolution and the authors could not \"identify features associated with the scattering of bromine and iodine\". The crystal structures in the \"ts2-inactive\" background are of even lower resolutions (4.69 and 6.12Å), though there were \"clear density for Br- and I- atoms of the paroxetine derivatives in subsite C\". Thus, given that the CC of ACB pose, 0.70, is not unacceptably low, there is no definitive evidence presented to specifically argue for the ABC and against the ACB pose. In addition, as -F to -Br and -I may significantly change the properties of the compound (see Abramyan, et al., 2018), it is not safe to assume that Br- or I-paroxetine are in the same pose as paroxetine. See https://www.ncbi.nlm.nih.gov/pubmed/27982595. Indeed, it is difficult for the cryo-EM and X-ray crystallography work to consider dynamics, thus the authors should not completely exclude the possibility of an ACB pose (see Discussion).

We appreciate this comment and given the moderate resolution of the x-ray data, the reviewer is correct that we would not expect to see the ACB pose if it is present at low occupancy. The CC of the ACB pose is 0.7 compared to 0.84 of the ABC pose and thus we agree that we cannot exclude the possibility of the ACB pose. We note that both via x-ray crystallography and cryo-EM that all three variants of paroxetine occupy a pose that could be best described as ABC pose, under the conditions of structure determination. Nonetheless, we agree that it is not possible to exclude ACB pose based on the data that we presented in the manuscript. The Discussion section has been edited to reflect these changes.

> 2\) Importantly, there appear to be some misinterpretations of the studies described in Abramyan et al., 2018 and Slack et al., 2019, that must be addressed:
>
> • \"However, recent mutagenesis, molecular dynamics, and binding studies with paroxetine analogues suggest that paroxetine may occupy two distinct poses in which the benzodioxol and fluorophenyl groups reside in subsite B or C, depending on the rotameric position of Phe341 and the presence of the thermostabilizing mutation Thr439Ser18,20 (ACB pose, Figure 1C).\" The main points in Abramyan et al., 2018 and Slack et al., 2019, were that the favored entropy component may play a significant role in paroxetine\'s high affinity, which include the dynamics in the S1 site (e.g., the dynamics of Phe341 in the presence of paroxetine but not Br-paroxetine) and potential pose ambiguity. The mutations may disrupt such dynamics but not necessarily associated with a specific pose.

This statement in the Introduction, has now been edited to read as follows "However, recent mutagenesis, molecular dynamics, and binding studies with paroxetine analogues suggest that paroxetine might either occupy the ABC pose as observed in the crystal structure, or an ACB pose where the benzodioxol and fluorophenyl groups occupy subsite C and B of the central site respectively (Abramyan et al., 2019; Slack et al., 2019) (Figure 1C)."

> • Regarding the synthesis of Br- and I-paroxetine analogues, this alternative approach is indeed new, however the authors should acknowledge that Br-paroxetine was previously synthesized and fully characterized in Slack et al., 2019.

We have now acknowledged the previous reports mentioning synthesis and complete characterization of Br-paroxetine in the Results section. We added a statement that says "In contrast, common methods for (--)-paroxetine synthesis can require the aromatic substituent to be introduced before stereoselective steps or ring construction, reducing flexibility of the process (Slack et al., 2019; Johnson et al., 2001; Hughes, Kimura and Buchwald, 2003; Brandau et al., 2006; Krautwalk et al., 2014; Wang et al., 2015; Kubota et al., 2016; Amat et al., 2000), nevertheless, Br-paroxetine and other analogues of paroxetine have been previously synthesized by these methods and binding to SERT has been extensively studied (Slack et al., 2019; Brandau et al., 2006)."

> • \"In this study, the authors hypothesized that the difference could be because of the crystallization conditions and thermostabilizing mutations.\" It is not clear what \"this study\" is referring to. Davis et al., 2016, did not discuss the crystal structures, while Abramyan et al. did not hypothesize that WT should be in the ACB pose (see above).

We have edited the last paragraph to read:

"However, computational docking experiments using wild-type SERT predicted that the position of benzodioxol and fluorophenyl groups of paroxetine are "flipped", with paroxetine occupying an ACB pose (David et al., 2016) (Figure 1C). Subsequent studies involving wild-type and mutant SERT variants that include modelling, mutagenesis, and Br-paroxetine docking experiments suggested that paroxetine could bind in both ABC and ACB poses. These studies also suggested that bromination of paroxetine and certain mutations near the central site, such as A169D, favored ABC pose (Abramyan et al., 2018; Slack et al., 2019). Hence, the authors in these studies hypothesized that the ABC pose observed in the crystal structure could be because of the crystallization conditions and thermostabilizing mutations."

> • Importantly, the dominant occupation of Br-paroxetine in the ABC pose is consistent with the findings in Slack et al., 2019 and should be acknowledged, as the studies in the present report for this compound were why it was synthesized in the first place. Based on the molecular dynamics studies in Abramyan et al., the studies in the present report neither support nor refute that paroxetine may bind in either pose in the native hSERT.

In multiple SERT structures, solved using both x-ray crystallography and cryo-EM, all three (F-, Br-, and I-) variants of paroxetine at the central site could be interpreted to be in an ABC pose. Based on these observations, we believe that bromination alone is not the reason for the ABC pose. However, we have now edited the text in Discussion and Results to indicate that while the ABC pose is favored in the conditions that we solved the structures, the possibility of the ACB pose cannot be excluded.

[^1]: These authors contributed equally to this work.
